Immune system disorder
MONDO:0005046A disorder resulting from an abnormality in the immune system.
Also known as: disease of immune system, disease or disorder of immune system, disorder of immune system, immune disease, immune disorder, immune dysfunction, immune system disease or disorder, immune system disorder
11427 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 1445 trials in this tab.
-
New MS drug trial for kids: could ocrelizumab help?
Disease control Not yet recruitingThis study tests a drug called ocrelizumab in children and teens aged 10 to 17 with relapsing-remitting multiple sclerosis (MS). The goal is to see how the drug moves through the body, if it is safe, and how it affects the immune system. Participants will receive the drug as a sh…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat myeloma
Disease control Not yet recruitingThis study tests a new treatment called AZD4045, which uses specially engineered immune cells (CAR-T cells) to target and kill multiple myeloma cells. The therapy is given alone or combined with other drugs (daratumumab and aldesleukin) in adults whose myeloma has returned or sto…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope for rare immune disorders: upadacitinib trial launches
Disease control Not yet recruitingThis study tests the drug upadacitinib (Rinvoq) in 30 people with rare genetic disorders that overactivate the JAK-STAT immune pathway. The trial has four phases over 12 months, including an open-label phase to find the best dose and a randomized withdrawal phase to compare the d…
Phase: PHASE1, PHASE2 • Sponsor: Lisa Satter • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope for young adults with CML: asciminib under Real-World scrutiny
Disease control Not yet recruitingThis study looks at how well the drug asciminib works and how safe it is for young adults with chronic myeloid leukemia (CML) in the Gulf region. Researchers will collect information from medical records of about 80 people aged 18 and older who have taken asciminib. The main goal…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Quarter-Sized implant could free type 1 diabetes patients from daily insulin
Disease control Not yet recruitingThis early-stage trial tests a small, soft implant that holds donor insulin-making cells (islets) and protects them from the immune system. The goal is to see if the device is safe and keeps the cells alive and working in adults with type 1 diabetes. Some participants are also on…
Phase: PHASE1 • Sponsor: Encellin • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Two-Drug sequence aims to clear CLL cells and let patients stop treatment
Disease control Not yet recruitingThis phase 2 trial tests a treatment plan for people with newly diagnosed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Participants first take zanubrutinib alone for 12 cycles, then add sonrotoclax for another 12 cycles. The goal is to see if this seque…
Phase: PHASE2 • Sponsor: Yi Shuhua • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Cream-and-Steroid combo aims to recolor vitiligo patches
Disease control Not yet recruitingThis study tests whether a cream containing ruxolitinib (Opzelura) combined with corticosteroid injections or pills can improve facial vitiligo. It includes people aged 12 and older with active, non-segmental vitiligo affecting the face. Participants use the cream twice daily and…
Sponsor: ShanShan Li • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Experimental cell therapy takes on tough leukemia
Disease control Not yet recruitingThis early-phase trial tests a new treatment called TSLPR-CART for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified in a lab to target a protein called TSLPR found on …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope for ITP patients: switching drugs after failed treatment
Disease control Not yet recruitingThis study looks at 112 people with immune thrombocytopenia (ITP) whose platelet counts didn't improve after standard treatment with rhTPO. After a two-week break, they will either get a higher dose of rhTPO or switch to a different drug called eltrombopag. The goal is to see whi…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Targeted combo aims at tough lymphoma subtype
Disease control Not yet recruitingThis phase 2 trial tests whether adding the targeted drug orelabrutinib to standard chemotherapy improves outcomes for people with a specific genetic subtype of diffuse large B-cell lymphoma (MCD subtype). Participants receive the drug combination during initial treatment, follow…
Phase: PHASE2 • Sponsor: Ou Bai, MD/PHD • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug KK2223 enters early human testing for Tough-to-Treat T-Cell lymphoma
Disease control Not yet recruitingThis early-stage trial is testing an experimental drug called KK2223 in 72 adults with T-cell lymphoma (a type of blood cancer) that has returned or not responded to prior treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processe…
Phase: PHASE1 • Sponsor: Kyowa Kirin, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for tough myeloma: early trial of BP2202 begins
Disease control Not yet recruitingThis early-stage trial is testing a new drug called BP2202 in 24 people with multiple myeloma that has come back or no longer responds to standard treatments. The main goal is to see if BP2202 is safe and to find the best dose. Researchers will also watch for any signs that the d…
Phase: PHASE1 • Sponsor: BrightPath Biotherapeutics Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a diabetes injection curb cannabis cravings? small trial aims to find out
Disease control Not yet recruitingThis 12-week study tests whether a weekly injection of tirzepatide, a drug used for diabetes, combined with motivational therapy can help adults with moderate to severe cannabis use disorder. Fifteen participants will receive escalating doses of tirzepatide along with counseling.…
Phase: PHASE3 • Sponsor: McMaster University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New pill hopes to calm Crohn's Flare-Ups
Disease control Not yet recruitingThis early-stage study tests a new drug called zasocitinib (TAK-279) in 20 adults with active Crohn's disease who have not responded to other treatments. The main goal is to see if the drug is safe and how it affects inflammation in the gut. Participants will take the drug for 12…
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Combination therapy aims to outsmart tough lymphoma
Disease control Not yet recruitingThis phase 2 trial tests whether adding the drug nemtabrutinib to a CAR T-cell therapy called brexu-cel can help people with mantle cell lymphoma that has come back or not responded to treatment. Nemtabrutinib blocks a protein that helps cancer cells grow, while brexu-cel uses a …
Phase: PHASE2 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Triple-Drug cocktail targets Hard-to-Treat blood cancers
Disease control Not yet recruitingThis phase I trial is testing whether combining three drugs—pacritinib, venetoclax, and azacitidine—is safe and tolerable for people with accelerated or blast phase myeloproliferative neoplasms, aggressive blood cancers. The study enrolls about 20 adults whose disease has progres…
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
One pill may tame both itchy skin and stubborn liver disease
Disease control Not yet recruitingThis study tests whether upadacitinib, a drug already approved for eczema, can help people who have both atopic dermatitis (a type of eczema) with moderate to severe itching and a hard-to-treat autoimmune liver disease called cholangitis. The drug works by blocking a pathway invo…
Phase: PHASE2 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat T-Cell cancers
Disease control Not yet recruitingThis study tests a new treatment called nano CD5-CAR T cells for people with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoma. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that carry the CD5 pro…
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Herbal mix and cancer drug join forces to fight fluid in lungs
Disease control Not yet recruitingThis study tests whether adding a Chinese herbal formula (Xuanyin Ning) to a standard cancer drug (bevacizumab) can better control malignant pleural effusion—fluid buildup in the chest caused by advanced lung cancer. About 308 participants will receive either the herbal formula o…
Phase: NA • Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug aims to wipe out hidden leukemia cells
Disease control Not yet recruitingThis phase 2 trial tests the drug mosunetuzumab in 30 people with chronic lymphocytic leukemia (CLL) who still have detectable cancer cells after at least six months of standard therapy. The goal is to see if the drug can clear those remaining cells and improve outcomes. Particip…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn blood cancers
Disease control Not yet recruitingThis phase 1 trial is testing a new kind of CAR-T cell therapy, called LMY-922, for people with certain blood cancers that have not responded to standard treatments. The therapy uses donor immune cells engineered to target a protein called BAFF on cancer cells. The study aims to …
Phase: PHASE1 • Sponsor: Luminary Therapeutics • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug duo aims to wipe out leukemia cells in First-Line treatment
Disease control Not yet recruitingThis phase 2 trial tests two oral drugs, nemtabrutinib and venetoclax, as a first treatment for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if the combination can make cancer cells undetectable in the blood. About 25 adul…
Phase: PHASE2 • Sponsor: Jennifer Woyach • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New oral pill H021 aims to tame Crohn's Flare-Ups
Disease control Not yet recruitingThis phase 2 trial tests whether an experimental oral tablet called H021 can help people with moderate to severe Crohn's disease. Participants receive either a low or high dose of H021 or a placebo for 12 weeks, with an option to continue treatment. The study measures symptom imp…
Phase: PHASE2 • Sponsor: Jiangsu Carephar Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Engineered immune cells take aim at autoimmune diseases
Disease control Not yet recruitingThis early-stage study is testing a new treatment called C-CAR168 for people with autoimmune diseases like multiple sclerosis, lupus, and myasthenia gravis that have not improved with standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab…
Phase: PHASE1 • Sponsor: The Affiliated Hospital of Qingdao University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New cocktail aims to tackle tough lymphoma
Disease control Not yet recruitingThis early-stage trial tests whether adding sonrotoclax to standard Pola-R-CHP chemotherapy can improve outcomes for people with untreated large B-cell lymphoma that has high BCL2 expression or double-hit features. The study has two parts: first, finding a safe dose of sonrotocla…
Phase: PHASE1, PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for kids: drug may prevent transplant complications
Disease control Not yet recruitingThis study tests whether adding the drug vorinostat to standard care can prevent graft-versus-host disease (GVHD) in children and young adults (ages 1-26) with non-cancerous blood disorders who are getting a bone marrow transplant. GVHD is a serious complication where donor cells…
Phase: PHASE2 • Sponsor: Sung Won Choi • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Radiation boost may supercharge CAR T-Cell therapy against tough lymphoma
Disease control Not yet recruitingThis trial tests whether adding low-dose total body irradiation (TBI) to standard chemotherapy before CAR T-cell therapy (tisagenlecleucel) is safe and effective for adults with large B-cell lymphoma that has returned or not responded to prior treatments. The study involves 18 pa…
Phase: PHASE1 • Sponsor: Nathan Denlinger • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Off-the-Shelf immune cells take aim at Hard-to-Treat leukemia
Disease control Not yet recruitingThis early-phase trial is testing an experimental therapy called GT737 for adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatment. GT737 uses specially engineered immune cells (iNKT cells) that are made in large batches and can be given…
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Dual-Pronged CAR T-Cell therapy takes aim at Hard-to-Treat leukemia
Disease control Not yet recruitingThis phase 1 trial tests a new cell therapy called KITE-753 for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. KITE-753 is made from a patient's own immune cells, which are modified to recognize and attack leuke…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Triple-Drug cocktail aims to tame untreated CLL
Disease control Not yet recruitingThis phase 2 trial is testing whether a combination of three drugs—zanubrutinib, sonrotoclax, and obinutuzumab—can safely control chronic lymphocytic leukemia (CLL) in people who have not yet received treatment. About 40 participants will receive all three drugs orally. The main …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Three-Drug cocktail aims to tame transplant complications in blood cancer patients
Disease control Not yet recruitingThis trial investigates whether adding bortezomib and sitagliptin to standard post-transplant cyclophosphamide can prevent graft-versus-host disease (GvHD) in adults with blood cancers receiving a stem cell transplant. Participants receive the drug combination after transplant, w…
Phase: PHASE1, PHASE2 • Sponsor: Northwell Health • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New Three-Drug cocktail aims to beat aggressive leukemia
Disease control Not yet recruitingThis study tests a new combination of three drugs—revumenib, azacitidine, and venetoclax—in people newly diagnosed with a specific, hard-to-treat leukemia called KMT2A-rearranged AML. The goal is to see if this cocktail can help more patients achieve remission with fewer side eff…
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug aims to ease daily struggles of myasthenia gravis
Disease control Not yet recruitingThis study tests an experimental drug called empasiprubart in people with a specific type of generalized myasthenia gravis (gMG) who have AChR antibodies. The goal is to see if the drug is safe and can improve symptoms like muscle weakness that affect daily activities. Participan…
Phase: PHASE2 • Sponsor: argenx • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Engineered immune cells take aim at childhood autoimmune diseases
Disease control Not yet recruitingThis early-phase trial tests a single infusion of universal CAR-T cells (RD06-05) in 30 children and adolescents with severe autoimmune diseases, including lupus, scleroderma, and kidney inflammation. The cells are designed to target and calm overactive immune cells. The main goa…
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a drug calm the immune storm in severe abdominal infections?
Disease control Not yet recruitingThis study tests whether ulinastatin, a drug that reduces inflammation, can help patients with severe abdominal infections. The infection often causes the immune system to overreact, leading to organ failure and high risk of death. Researchers will give patients either a low or h…
Phase: NA • Sponsor: Fujian Medical University Union Hospital • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Can intense breathing training boost lung power and ease fatigue in MS?
Disease control Not yet recruitingThis study tests whether high-intensity breathing exercises can improve respiratory muscle strength, lung function, fatigue, and quality of life in people with multiple sclerosis (MS). Participants are randomly assigned to high-intensity interval breathing training, low-intensity…
Phase: NA • Sponsor: Istanbul University - Cerrahpasa • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New Two-Drug combo aims to beat back returning myeloma
Disease control Not yet recruitingThis study compares a new combination of teclistamab and pomalidomide against the standard treatment (carfilzomib, pomalidomide, and dexamethasone) for multiple myeloma that has come back after improvement. About 162 adults with relapsed or refractory myeloma will take part. The …
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a simple antibiotic keep blood cancer patients out of the hospital?
Disease control Not yet recruitingThis study tests whether taking a daily antibiotic (levofloxacin) can safely reduce infections in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) who are receiving chemotherapy as outpatients. The trial will randomly assign 75 participants to either lev…
Phase: PHASE2 • Sponsor: University of Manitoba • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Experimental CAR T-Cell therapy targets tough lymphoma
Disease control Not yet recruitingThis early-phase trial tests a new type of immune cell therapy called GoFast CD19 CAR T-cells in 9 adults with relapsed or refractory large B-cell lymphoma. Participants receive chemotherapy followed by an infusion of their own modified immune cells. The study aims to see if the …
Phase: EARLY_PHASE1 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New antibody drug aims to save Insulin-Making cells in type 1 diabetes
Disease control Not yet recruitingThis Phase 3 study tests SAB-142, an antibody that targets immune cells, in 108 people aged 5 to 40 with type 1 diabetes. The goal is to see if it can preserve the body's ability to produce insulin over 12 months. Participants receive either the drug or a placebo alongside standa…
Phase: PHASE3 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New asthma shot could help kids breathe easier
Disease control Not yet recruitingThis study tests a new injectable drug called depemokimab in 30 children aged 6 to 11 with asthma that involves a specific type of inflammation. The drug is given alongside their usual asthma medicines to see how the body processes it, how well it works, and if it is safe. The go…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Engineered yeast pill takes on superbug c. diff in first human trial
Disease control Not yet recruitingThis early-stage trial tests an oral capsule containing a genetically modified probiotic yeast designed to neutralize toxins produced by C. diff bacteria. The study first evaluates safety in healthy adults, then in people at risk for recurrent C. diff infection. Participants take…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug cocktail aims to deepen remission in multiple myeloma patients
Disease control Not yet recruitingThis Phase 3 trial tests whether adding the drug Teclistamab to a standard treatment regimen (Daratumumab, Lenalidomide, Bortezomib, Dexamethasone) improves outcomes for newly diagnosed multiple myeloma patients eligible for stem cell transplant. About 399 adults aged 18-70 will …
Phase: PHASE3 • Sponsor: University of Heidelberg Medical Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Can a special diet calm Crohn's Flare-Ups?
Disease control Not yet recruitingThis study tests whether a specially designed anti-inflammatory diet can reduce symptoms and gut inflammation in people with mild-to-moderate Crohn's disease. For 8 weeks, 122 participants will receive fully catered meals and weekly coaching from a dietitian. The goal is to see i…
Phase: NA • Sponsor: University of Miami • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New eye drops aim to calm Sjögren's dry eye by blocking inflammation
Disease control Not yet recruitingThis phase 2 trial tests whether eye drops containing infliximab, a drug that blocks a key inflammatory protein, can safely improve severe dry eye in people with Sjögren's syndrome. 38 adults will receive either the active drops or a steroid drop for 6 weeks. The study measures s…
Phase: PHASE2 • Sponsor: Instituto de Oftalmología Fundación Conde de Valenciana • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for myeloma: experimental drug combo aims to beat standard care
Disease control Not yet recruitingThis phase 2 trial compares two drug combinations for people newly diagnosed with multiple myeloma who are not eligible for or have deferred a stem cell transplant. One group gets the experimental drug elranatamab plus standard medications (lenalidomide, bortezomib, dexamethasone…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New hope for myeloma patients: could ramantamig plus daratumumab outperform standard care?
Disease control Not yet recruitingThis phase 3 trial will compare a new treatment, ramantamig plus daratumumab, against two standard drug combinations for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The study aims to see if the new combo can keep the cancer from p…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Can diet help people with type 1 diabetes lose weight? new study aims to find out
Disease control Not yet recruitingThis study compares three diets for weight loss in adults with type 1 diabetes who are overweight or obese. Participants will follow either a moderate carbohydrate restriction, an early time-restricted eating plan, or a standard calorie-restricted diet. The goal is to see which a…
Phase: NA • Sponsor: Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New study tests Anti-Inflammatory drug for Crohn's in china
Disease control Not yet recruitingThis study will test the drug Tabellvi (adalimumab) in 50 Chinese adults with moderate to severe Crohn's disease. The goal is to see how safe and effective it is in real-world settings, focusing on side effects and whether patients achieve remission after 26 weeks. Participants m…
Phase: PHASE4 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Can bringing addiction treatment to syringe programs save more lives?
Disease control Not yet recruitingThis study tests whether offering buprenorphine treatment directly at syringe service programs (SSPs) helps more people start and stay on medication for opioid use disorder compared to referring them elsewhere. About 512 adults who use SSPs and have moderate to severe opioid use …
Phase: NA • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Experimental CAR-T therapy takes on tough lupus cases
Disease control Not yet recruitingThis early-stage trial tests a new treatment called P-CD19CD20-ALLO1, a type of CAR-T cell therapy, for people with severe lupus that hasn't improved with standard treatments. The study will enroll 162 participants and aims to check if the therapy is safe and tolerable. It also l…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Ancient herbs meet modern medicine: can Curcumin-QingDai tame UC?
Disease control Not yet recruitingThis study tests whether adding a combination of curcumin (from turmeric) and QingDai (a traditional Chinese herb) to standard vedolizumab treatment can help people with moderate to severe ulcerative colitis reach remission. About 160 adults will receive either the herbal combo o…
Phase: PHASE4 • Sponsor: Ryan C Ungaro • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a cholesterol drug and antioxidant help treat a rare bleeding disorder?
Disease control Not yet recruitingThis trial investigates whether combining atorvastatin (a cholesterol-lowering drug), N-acetyl-L-cysteine (an antioxidant), and romiplostim (a platelet-boosting drug) can help adults with immune thrombocytopenia (ITP) who no longer respond to steroids. The goal is to see if this …
Phase: NA • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
12,000 diabetes patients to test remote monitoring system
Disease control Not yet recruitingThis study will look at whether a remote patient monitoring system, called Steno Detektor, helps people with diabetes control their blood sugar. About 12,000 patients will be monitored as part of their regular care. Researchers will compare blood sugar levels and hospital visits …
Sponsor: Steno Diabetes Center Copenhagen • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New study aims to stop blood cancer relapse after transplant
Disease control Not yet recruitingThis study tests whether giving personalized maintenance therapy after a stem cell transplant can prevent cancer from coming back in people with certain blood cancers. About 450 adults with myeloid cancers who have signs of disease before transplant will be assigned to treatment …
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Crohn's blockage showdown: drugs or surgery for better quality of life?
Disease control Not yet recruitingThis trial compares two approaches for people with Crohn's disease who have a narrowed section of the small bowel causing symptoms. One group receives a combination of two drugs (azathioprine and infliximab), while the other group undergoes surgery to remove the narrowed segment.…
Phase: NA • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New skin cell transplant combo aims to restore color in white patches
Disease control Not yet recruitingThis study tests two surgical techniques to treat stable white patches on the skin that are not caused by vitiligo. Both methods involve transplanting the patient's own skin cells, followed by laser therapy to boost color return. Twenty-two adults will each receive both treatment…
Phase: NA • Sponsor: Al-Azhar University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail aims to tackle tough lymphoma
Disease control Not yet recruitingThis study tests a combination of two drugs, glofitamab and selinexor, in 30 adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have already tried at least two other treatments. The goal is to see how many patients achieve a complete response (cancer dis…
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a simpler eczema routine boost treatment success?
Disease control Not yet recruitingThis study explores whether giving people with mild-to-moderate eczema a straightforward treatment plan using only Opzelura cream helps them stick to their medication routine. Participants apply the cream twice daily until their skin clears, then as needed. Some participants also…
Phase: PHASE4 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Can a cancer drug tame a dangerous immune storm?
Disease control Not yet recruitingThis early study tests the drug ruxolitinib for a rare but serious condition called IEC-HS, which can happen after CAR-T therapy for cancer. The condition causes a dangerous overreaction of the immune system. The trial will include 16 adults and aims to see if the drug is safe an…
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to tame liver side effects of cancer immunotherapy
Disease control Not yet recruitingThis study tests whether combining mycophenolate mofetil (MMF) with prednisone can better treat liver inflammation caused by checkpoint inhibitor cancer drugs. The trial includes adults with moderate to severe immune-related hepatitis who need to pause their cancer therapy. The m…
Phase: PHASE2 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug takes aim at Hard-to-Treat blood cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called LY4152199 in about 215 adults with certain types of blood cancer (like follicular lymphoma or diffuse large B-cell lymphoma) that have already been treated. The drug is designed to help the body's immune cells attack the cancer. The …
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo shows promise for aggressive lymphoma
Disease control Not yet recruitingThis phase 2 trial tests whether adding the drug epcoritamab to standard chemotherapy (DA-EPOCH-R) helps people with high-risk Burkitt lymphoma. About 43 adults will receive the combination. The study will check how many complete at least three cycles of treatment and track overa…
Phase: PHASE2 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo therapy aims to boost platelets in ITP patients
Disease control Not yet recruitingThis phase 2 trial tests whether adding baricitinib to standard TPO-RA therapy helps adults with immune thrombocytopenia (ITP) who did not respond to TPO-RA alone. One hundred participants will be randomly assigned to receive either baricitinib plus TPO-RA or TPO-RA alone for 14 …
Phase: PHASE2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for AML patients: gentler drug combo could replace harsh chemo
Disease control Not yet recruitingThis study compares a new drug combination (venetoclax plus azacitidine) against standard chemotherapy for adults with a specific type of acute myeloid leukemia (AML) that has NPM1 or IDH mutations. About 148 people will be randomly assigned to one of the two treatments. The main…
Phase: PHASE2 • Sponsor: Shen yang • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Zapping kidney nerves: a Needle-Free hope for high blood pressure?
Disease control Not yet recruitingThis pilot study tests a new device that uses radiofrequency energy to calm overactive kidney nerves, which can drive high blood pressure. Twenty adults with untreated mild hypertension will either get the real procedure or a sham (fake) one. The main goal is to see if the real t…
Phase: NA • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for kids with ITP: drug combo aims to control bleeding
Disease control Not yet recruitingThis phase 2 trial tests whether adding ianalumab to eltrombopag helps children aged 5 to 17 with primary immune thrombocytopenia (ITP) who didn't improve after steroids. The goal is to see if the combination can raise platelet counts and prevent bleeding. About 36 children will …
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill aims to bring back color to vitiligo skin
Disease control Not yet recruitingThis phase 2a trial tests whether a daily pill called ACT-777991 can help return color to the face of adults with non-segmental vitiligo. About 30 participants will take either the drug or a placebo for 24 weeks. Researchers will measure changes in skin color using a standard sco…
Phase: PHASE2 • Sponsor: Idorsia Pharmaceuticals Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New dosing strategy aims to reduce eye side effects in myeloma treatment
Disease control Not yet recruitingThis phase 2 trial is testing whether different dosing schedules of belantamab mafodotin, when combined with bortezomib and dexamethasone, can reduce the risk of serious eye problems while still controlling multiple myeloma. About 150 adults with relapsed or refractory multiple m…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug hope for kids with MS: ublituximab trial launches
Disease control Not yet recruitingThis study tests the drug ublituximab in children aged 10 to 18 with relapsing multiple sclerosis (MS). It compares ublituximab to another drug, fingolimod, to see which better controls relapses. The trial involves 240 participants and will also monitor long-term safety and effec…
Phase: PHASE2, PHASE3 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Hope for scleroderma: new pill aims to halt disease progression
Disease control Not yet recruitingThis Phase 3 trial tests whether the oral drug nerandomilast can slow disease progression in adults with systemic sclerosis (scleroderma). About 448 participants will be randomly assigned to receive either nerandomilast or a placebo twice daily for up to 4 years. Researchers will…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug trial aims to ease muscle weakness in rare disease
Disease control Not yet recruitingThis study tests a drug called ravulizumab in 20 Chinese adults with generalized myasthenia gravis, a condition that causes severe muscle weakness. The drug is given through a vein and works by blocking a part of the immune system to reduce symptoms. Researchers will measure how …
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Smart blood pressure cuffs could protect cancer patients from heart risks
Disease control Not yet recruitingThis pilot study tests whether a connected blood pressure monitor, supervised daily by a healthcare assistant, helps patients with blood cancers like CLL or lymphoma stick to home monitoring. The goal is to catch and manage high blood pressure early, a common side effect of BTK i…
Phase: NA • Sponsor: Centre Hospitalier de la côte Basque • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug shows promise for severe eczema in toddlers
Disease control Not yet recruitingThis study tests a drug called nemolizumab in toddlers aged 6 to 23 months with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with creams or ointments. The goal is to see how the drug moves through the body, if it is safe, and if it helps control the conditio…
Phase: PHASE2 • Sponsor: Galderma R&D • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New trial combines HIV PrEP and STI prevention in one package for young men
Disease control Not yet recruitingThis study tests whether a combined approach—offering HIV PrEP (pills or injections) and STI prevention (doxycycline after sex) along with smartphone tools—helps young men at high risk stay protected. About 400 men aged 18-29 who have sex with men will be followed for a year to s…
Phase: PHASE3 • Sponsor: HIV Prevention Trials Network • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New daily pill aims to tackle Hard-to-Treat lymphoma
Disease control Not yet recruitingThis study tests an experimental daily pill called HP-002 in people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. It includes several ly…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Helioson Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Engineered immune cells take aim at Hard-to-Treat lupus
Disease control Not yet recruitingThis trial tests a one-time treatment called CAR-T cell therapy for people with systemic lupus erythematosus (lupus) that hasn't improved with standard medications. The therapy uses a patient's own immune cells, which are modified in a lab to find and destroy the B cells that dri…
Phase: PHASE1, PHASE2 • Sponsor: University of Sao Paulo • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug candidate SHR-3079 targets Hard-to-Treat lymphoma
Disease control Not yet recruitingThis trial tests a new drug called SHR-3079 in adults with B-cell non-Hodgkin lymphoma whose cancer has not responded to at least one prior standard treatment. The main goals are to check the drug's safety, find the best dose, and get an early look at whether it can shrink tumors…
Phase: PHASE1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New uganda trial tackles alcohol and HIV care for men with pregnant partners
Disease control Not yet recruitingThis pilot study tests a program called Kisoboka Amaka for men living with HIV who drink heavily and have pregnant partners. The program combines counseling, financial training, and mobile savings to help men drink less and take their HIV medication consistently. Researchers will…
Phase: NA • Sponsor: San Diego State University • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New pill aims to keep leukemia away after transplant
Disease control Not yet recruitingThis study tests a new oral drug called revumenib in people with acute myeloid leukemia (AML) who have certain genetic changes. After a stem cell transplant, participants will take revumenib or a placebo to see if it helps keep the cancer from coming back. The trial involves 144 …
Phase: PHASE2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Selective cell removal may tame stem cell Transplant's dangerous side effect
Disease control Not yet recruitingThis study tests whether removing a specific type of immune cell (naive T cells) from a donor's stem cell graft can prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the recipient's body. The trial enrolls people with non-malignant blood di…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New trial puts mirikizumab Head-to-Head with standard Crohn's therapy
Disease control Not yet recruitingThis study compares early treatment with mirikizumab (a biologic drug) to standard therapy with azathioprine plus steroids in 320 adults newly diagnosed with moderate-to-severe Crohn's disease. Participants are randomly assigned to one of two groups for 52 weeks. The goal is to s…
Phase: PHASE4 • Sponsor: University Hospital Schleswig-Holstein • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Free veggies and cooking classes aim to tame diabetes in pregnancy
Disease control Not yet recruitingThis study tests a program that delivers fresh produce to the homes of pregnant women with type 1 or 2 diabetes who also struggle to afford healthy food. Participants also get group classes on diabetes, nutrition, and cooking, plus help finding other resources. The goal is to see…
Phase: NA • Sponsor: Ohio State University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for tough lymphoma: experimental drug GSK5926371 enters human trials
Disease control Not yet recruitingThis early-stage trial tests a new drug called GSK5926371 in about 49 adults with B-cell non-Hodgkin lymphoma that has returned or not responded to at least two prior treatments. The main goals are to check the drug's safety and see if it can shrink tumors. Researchers will also …
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to boost remission in tough AML cases
Disease control Not yet recruitingThis study tests a new combination of drugs (chidamide, venetoclax, azacitidine, and homoharringtonine) as a first treatment for adults aged 18-60 with intermediate- to high-risk acute myeloid leukemia (AML). The goal is to see if this mix can improve remission rates and reduce t…
Phase: PHASE2 • Sponsor: Dongguan People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New antibody cocktail targets stubborn liver disease after stem cell transplants
Disease control Not yet recruitingThis study tests a lab-made antibody called anti-CD25 rhMAb for people with chronic graft-versus-host disease (cGVHD) of the liver that hasn't improved with steroids. The antibody is given alongside standard immune-suppressing drugs. The trial will include 30 adults aged 16-65 wh…
Phase: PHASE4 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental drug aims to tame stubborn autoimmune diseases
Disease control Not yet recruitingThis early study tests an experimental drug called STR-P005 in people with autoimmune diseases that have come back or not improved with standard treatments. The drug is given through an IV in multiple doses. The main goal is to check safety and see how the body handles the drug. …
Phase: NA • Sponsor: Starna Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a stomach shield drug replace acid blockers for steroid users?
Disease control Not yet recruitingThis study tests whether teprenone, a stomach-protecting drug, can reduce gastrointestinal damage caused by high-dose steroids in people with lupus. One hundred participants will be randomly assigned to take either teprenone or the standard acid-blocker omeprazole for 12 weeks. T…
Phase: NA • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug hope for GPA patients with stubborn ENT symptoms
Disease control Not yet recruitingThis study tests whether adding TAVNEOS to standard treatment helps control ear, nose, and throat symptoms in people with granulomatosis with polyangiitis (GPA). About 30 adults with active ENT disease will receive either TAVNEOS or a placebo for 52 weeks. The goal is to see if m…
Phase: PHASE2, PHASE3 • Sponsor: Robert Spiera, MD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for rare leukemia: Four-Drug cocktail targets cancer cells
Disease control Not yet recruitingThis phase 2 trial tests a new drug combination for adults newly diagnosed with primary plasma cell leukemia, a rare and aggressive blood cancer. The treatment includes CM336 (a bispecific antibody) plus three other drugs. The study aims to see how many patients achieve deep remi…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could an antibody boost chemo for tough blood cancers?
Disease control Not yet recruitingThis large clinical trial is testing whether adding the drug daratumumab to standard chemotherapy helps children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL). Daratumumab is an antibody that targets a pr…
Phase: PHASE2, PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a common liver drug replace steroids for immunotherapy side effects?
Disease control Not yet recruitingThis phase 2 trial tests whether ursodeoxycholic acid (UDCA), a drug already used for other liver conditions, can treat cholestatic hepatitis—a liver inflammation caused by immunotherapy—better than standard steroids. About 94 adults with cancer (excluding liver cancer) who devel…
Phase: PHASE2 • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Smart inhalers track Fasenra's asthma control over full dosing cycle
Disease control Not yet recruitingThis study tracks people with severe eosinophilic asthma who already take Fasenra (benralizumab) every 8 weeks. Participants use electronic monitors on their regular inhalers and a study-provided rescue inhaler (AirSupra) to see if asthma control stays steady throughout the dosin…
Phase: PHASE4 • Sponsor: Endeavor Health • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a drug stop dangerous side effects of new myeloma therapies?
Disease control Not yet recruitingThis phase 2 trial tests whether infliximab, a drug that blocks inflammation, can prevent cytokine release syndrome (CRS) in people with relapsed or refractory multiple myeloma receiving teclistamab or talquetamab. CRS is a common and sometimes serious side effect of these treatm…
Phase: PHASE2 • Sponsor: Naresh Bumma • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug SHR-5421 takes on Hard-to-Treat multiple myeloma
Disease control Not yet recruitingThis early-phase trial is testing a new drug, SHR-5421, in about 97 people with multiple myeloma that has come back or stopped responding to treatment. The main goal is to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the bo…
Phase: PHASE1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to shield autoimmune patients from Life-Threatening infections
Disease control Not yet recruitingThis study tests whether a medicine called Panzyga can prevent major infections in people with autoimmune or rheumatic conditions who have low antibody levels after receiving B-cell depletion therapy. About 360 adults will receive either Panzyga or a placebo, and researchers will…
Phase: PHASE3 • Sponsor: Octapharma • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Heart-Safe chemo? trial aims to shield patients from lifelong damage
Disease control Not yet recruitingThis study tests two different drugs—dexrazoxane and liposomal doxorubicin—to see which is safer and more effective at preventing heart failure in people with a type of lymphoma called DLBCL. All 60 participants will receive standard chemotherapy (R-CHOP or pola-R-CHP), and the g…
Phase: PHASE2 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a maintenance drug keep lymphoma at bay? new trial aims to find out.
Disease control Not yet recruitingThis phase 2 trial tests whether giving rituximab maintenance therapy after initial treatment with rituximab and lenalidomide (R2) can improve outcomes for people with untreated marginal zone lymphoma. About 144 patients who respond to R2 will be randomly assigned to receive ritu…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a stem cell shot before birth fix fanconi anemia?
Disease control Not yet recruitingThis early-phase trial tests whether giving healthy stem cells from the mother to a fetus diagnosed with Fanconi anemia can safely improve the baby's blood cell production. The treatment is a one-time injection into the fetus during pregnancy. The study will enroll 12 pregnant wo…
Phase: PHASE1, PHASE2 • Sponsor: Agnieszka Czechowicz • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Personalized immunotherapy strategies aim to improve outcomes for frail myeloma patients
Disease control Not yet recruitingThis phase 3 trial is for people newly diagnosed with multiple myeloma who are not healthy enough for a stem cell transplant. After six months of standard treatment with daratumumab, lenalidomide, and dexamethasone, participants are assigned to different immunotherapy combination…
Phase: PHASE3 • Sponsor: University of Leeds • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill aims to tame severe gut disease
Disease control Not yet recruitingThis study tests an experimental tablet called Hemay005 in 360 Chinese adults with moderate to severe ulcerative colitis, a chronic gut condition. Participants will receive either the drug or a placebo to see if it can bring about remission and improve symptoms over 12 weeks, wit…
Phase: PHASE3 • Sponsor: Ganzhou Hemay Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to lock in remission for rare lymphoma
Disease control Not yet recruitingThis study tests whether the drug elranatamab can help keep plasmablastic lymphoma, a rare and aggressive blood cancer, from returning after initial chemotherapy. About 17 adults with or without HIV who have already responded to first treatment will receive elranatamab injections…
Phase: PHASE2, PHASE3 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for cancer survivors: drug aims to shield against Life-Threatening infections
Disease control Not yet recruitingThis study tests a drug called IgPro20 in 63 adults who have a weakened immune system after receiving CAR T-cell therapy for blood cancers like lymphoma or multiple myeloma. The goal is to see if the drug can lower the number of serious bacterial infections, such as pneumonia or …
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for HIV patients with aggressive lymphoma: early trial launches
Disease control Not yet recruitingThis early-phase trial will test the safety and feasibility of adding the experimental drug glofitamab to standard chemoimmunotherapy (R-CHOP) in 15 people newly diagnosed with HIV-associated large B-cell lymphoma. Glofitamab is a bispecific antibody that helps the immune system …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to ease daily struggles of myasthenia gravis
Disease control Not yet recruitingThis phase 3 trial tests whether claseprubart (DNTH103) can improve symptoms of generalized myasthenia gravis, a condition causing muscle weakness. About 195 adults with a specific antibody type are randomly assigned to receive the drug or a placebo. The main goal is to see if th…
Phase: PHASE3 • Sponsor: Dianthus Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo targets Tough-to-Treat myeloma
Disease control Not yet recruitingThis phase 2 trial is testing a new drug called CM336, given alongside standard therapy, for people with high-risk multiple myeloma. The study will include 46 adults aged 18 to 75. The main goal is to see if the combination can reduce cancer cells to very low levels (MRD negativi…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a natural supplement calm ulcerative colitis?
Disease control Not yet recruitingThis study tests whether a supplement called palmitoylethanolamide (PEA) can help people with mild-to-moderate ulcerative colitis. Researchers will measure changes in disease activity, quality of life, and inflammation markers in 60 participants. The goal is to see if adding PEA …
Phase: NA • Sponsor: Ain Shams University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New shot plus light therapy aims to restore skin color in vitiligo
Disease control Not yet recruitingThis study tests a new medicine called GR2301, given as shots under the skin, together with light therapy for people with vitiligo (a condition that causes white patches on the skin). The trial has two parts: first, finding the right dose, then testing how well it works. About 11…
Phase: PHASE1, PHASE2 • Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to wipe out Hard-to-Treat leukemia and MDS
Disease control Not yet recruitingThis phase 2 trial tests whether adding olutasidenib to standard treatments helps people with IDH1-mutated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). For AML, the standard is a chemotherapy pill plus venetoclax; for higher-risk MDS, it's the chemotherapy pill…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Lifestyle makeover may slow early myeloma
Disease control Not yet recruitingThis study tests whether a year-long lifestyle program (diet, exercise, and other healthy habits) can improve key blood markers in people with MGUS or smoldering myeloma—two early, often symptom-free conditions that can lead to multiple myeloma. About 67 adults will participate, …
Phase: NA • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to cut blood removal in rare cancer
Disease control Not yet recruitingThis trial tests rusfertide, an injected drug, in Japanese adults with polycythemia vera, a rare blood cancer that causes too many red blood cells. The goal is to see if rusfertide can keep red blood cell levels under control and reduce the need for phlebotomy (blood removal). Al…
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to treat leukemia without harsh chemo
Disease control Not yet recruitingThis study tests whether combining two drugs, inotuzumab and blinatumomab, is safe and effective for adults newly diagnosed with B-cell acute lymphoblastic leukemia (B-ALL). The trial includes 26 people aged 18 and older who are either 55+ or cannot tolerate standard chemotherapy…
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
AI-Powered tool aims to sharpen MS treatment choices
Disease control Not yet recruitingThis study tests a computer program called PRIMUS that helps neurologists choose treatments for people with relapsing-remitting multiple sclerosis (MS). The tool uses data from past patients to predict how the disease might progress under different therapies. Doctors in some clin…
Phase: NA • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to tackle myeloma that resists CAR-T therapy
Disease control Not yet recruitingThis study tests a combination of two drugs, belantamab mafodotin and mezigdomide, in 44 adults with multiple myeloma whose cancer returned after treatment with CAR-T cells or bispecific antibodies. The goal is to see if the combo can control the cancer longer. The trial starts w…
Phase: PHASE1, PHASE2 • Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could less be more? new trial shortens leukemia drug course for seniors
Disease control Not yet recruitingThis study looks at whether giving the drug venetoclax for a shorter time, along with the combination drug ASTX727, works as well as the usual longer course for adults aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for strong chemot…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug HBM7020 tested in humans for first time against autoimmune diseases
Disease control Not yet recruitingThis first-in-human study tests the safety of a new drug called HBM7020. It will first be given to healthy volunteers at low doses, then to people with moderate to severe autoimmune diseases like lupus, rheumatoid arthritis, scleroderma, and Sjögren's disease. The goal is to see …
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to tame leukemia without lifelong pills
Disease control Not yet recruitingThis study tests whether combining dasatinib with ropeginterferon can better control chronic myeloid leukemia in its early phase. About 40 adults newly diagnosed with CML will receive the drug pair to see if it improves disease control and reduces side effects. The goal is to man…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Can a Macrophage-Targeting drug supercharge CAR-T therapy?
Disease control Not yet recruitingThis trial tests whether adding a drug called axatilimab to standard CAR-T cell therapy can improve outcomes for people with high-risk large B-cell lymphomas. Axatilimab works by conditioning macrophages, a type of immune cell, to potentially help the CAR-T cells fight cancer mor…
Phase: PHASE1 • Sponsor: Northside Hospital, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New combo pill attack aims to control blood cancers
Disease control Not yet recruitingThis study tests two experimental drugs (rocbrutinib and lacutoclax) taken together to treat several types of blood cancers, including lymphoma and leukemia. The goal is to see if the combination is safe and can shrink or control the cancer. About 92 adults who have already tried…
Phase: PHASE1, PHASE2 • Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Can a single drug stop JAK2 mutations from turning into cancer?
Disease control Not yet recruitingThis pilot study tests whether the drug ropeginterferon is safe and feasible for 12 people with a JAK2 mutation and high-risk features who do not yet have a blood cancer. Participants receive an injection every 4 weeks and are monitored closely. The goal is to see if this approac…
Phase: PHASE1 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New pill shows promise for Hard-to-Treat blood cancer
Disease control Not yet recruitingThis phase 2 trial tests lacutoclax, a daily pill that blocks a protein helping cancer cells survive, in 75 adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. Participants take the drug until their disease worsens or side effects become…
Phase: PHASE2 • Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New chemo cocktail aims to boost stem cell transplant success in leukemia
Disease control Not yet recruitingThis trial is testing a combination of three chemotherapy drugs—clofarabine, busulfan, and melphalan—given before a stem cell transplant in 30 adults with acute myeloid leukemia (AML) who are in first remission. The goal is to see if this conditioning regimen improves survival an…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New Dual-Targeting cell therapy takes aim at Hard-to-Treat blood cancers
Disease control Not yet recruitingThis early-phase study tests a new type of immune cell therapy (CAR T cells) that targets two proteins on cancer cells at once. It is for adults with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after other treatments. The main goal is to find a s…
Phase: PHASE1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New eczema pill shows promise in Mid-Stage trial
Disease control Not yet recruitingThis study tests an experimental pill called ENV-294 for adults with moderate-to-severe atopic dermatitis (eczema). About 200 participants will take either one of three doses of ENV-294 or a placebo daily for 12 weeks. Researchers will measure changes in eczema severity, symptoms…
Phase: PHASE2 • Sponsor: Enveda Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for stubborn Graft-Versus-Host disease: experimental drug combo enters early trial
Disease control Not yet recruitingThis early-phase study tests whether the drug sarilumab can safely help adults with chronic graft-versus-host disease (cGVHD) that did not improve with the standard drug belumosudil. Ten participants will receive sarilumab alone, and researchers will monitor side effects and drug…
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Poop pills could tame stubborn arthritis
Disease control Not yet recruitingThis study tests whether freeze-dried fecal bacteria, given as oral capsules, can improve symptoms in 40 adults with active rheumatoid arthritis that hasn't responded to standard drugs. Participants will receive either the fecal transplant or a placebo for 24 weeks. The main goal…
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New CAR-T therapy shows promise for tough leukemia in Real-World study
Disease control Not yet recruitingThis study will follow 200 Chinese patients with relapsed or refractory B-cell acute lymphoblastic leukemia who receive a CAR-T cell therapy called puzolcabtagene autoleucel. The goal is to see how well it works in everyday medical practice, measuring response rates and how long …
Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New study aims to tame dangerous immune reaction in myeloma therapy
Disease control Not yet recruitingThis study tests whether giving a single dose of tocilizumab before the cancer drug ramantamig can prevent or reduce cytokine release syndrome (CRS), a serious flu-like reaction. About 230 adults with relapsed or refractory multiple myeloma will participate. Half will get tociliz…
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Could a Two-Week chemo blast be just as good as three for AML?
Disease control Not yet recruitingThis study tests whether a two-week course of the VA-CAG chemotherapy works as well as the usual three-week course for adults newly diagnosed with acute myeloid leukemia (AML). About 110 participants will be randomly assigned to one of the two schedules. The goal is to see if the…
Phase: PHASE2 • Sponsor: Hematology department of the 920th hospital • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New trial aims to find best treatment for lung complication in rheumatoid arthritis
Disease control Not yet recruitingThis 52-week study will compare three drugs—tocilizumab, telitacicept, and methotrexate—in 204 people with rheumatoid arthritis who also have interstitial lung disease. The main goal is to see which drug best improves lung function. Participants will continue their usual arthriti…
Phase: PHASE4 • Sponsor: Chinese SLE Treatment And Research Group • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Blood clot risk in rare disease: could a higher dose of clopidogrel offer better protection?
Disease control Not yet recruitingThis study looks at whether a higher dose of the blood thinner clopidogrel works better for people with essential thrombocythemia (ET), a rare blood disorder that raises the risk of dangerous blood clots. The standard dose may not work well for many ET patients, so researchers wi…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug combo aims to tame transplant complication
Disease control Not yet recruitingThis phase 2 trial tests a combination of two oral drugs, ruxolitinib and belumosudil, for chronic graft-versus-host disease (cGvHD) that hasn't improved with steroids. cGvHD is a serious condition where donor immune cells attack the patient's body after a stem cell transplant. T…
Phase: PHASE2 • Sponsor: Dennis Kim • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Gentle exercise with cuffs may boost muscle in MS patients
Disease control Not yet recruitingThis study tests whether adding blood flow restriction cuffs to light leg exercises can help people with relapsing-remitting multiple sclerosis build bigger, stronger thigh muscles. Thirty participants will do the same exercise twice a week for 8 weeks, but some will have the cuf…
Phase: NA • Sponsor: Hanifi Bal • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New automated insulin system tested for hospital diabetes care
Disease control Not yet recruitingThis study tests a new automated insulin delivery system for people with type 1 or type 2 diabetes in a hospital setting. Six participants will have their blood sugar controlled by the system for 24 hours while eating standard meals. The goal is to see if the system can keep bloo…
Phase: NA • Sponsor: Ideal Medical Technologies • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combo therapy targets high-risk MDS in early trial
Disease control Not yet recruitingThis study tests a new two-drug combination (pacritinib plus azacitidine) for people with moderate to very high risk myelodysplastic syndrome (MDS), a bone marrow disorder. The first part finds the safest dose of pacritinib, and the second part checks how well the combination wor…
Phase: PHASE1, PHASE2 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Could a simple shot replace hospital stays for myeloma patients?
Disease control Not yet recruitingThis study tests whether the drug elranatamab can be given safely in an outpatient clinic instead of the hospital for people with multiple myeloma that has come back or stopped responding to treatment. About 46 adults will receive the drug along with a single preventive dose of a…
Phase: PHASE2 • Sponsor: SCRI Development Innovations, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for teens with rare nerve disease: drug trial launches
Disease control Not yet recruitingThis study tests a new medicine called empasiprubart in teenagers aged 12 to 17 who have a rare nerve disease called CIDP. The goal is to find the right dose and see if the drug is safe and helps control the disease. Participants will receive the drug for about 27 months and be f…
Phase: PHASE2, PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Real-World check: Asciminib's performance in Tough-to-Treat CML
Disease control Not yet recruitingThis study will follow about 98 adults with chronic myeloid leukemia who are taking asciminib after other treatments have stopped working. Researchers want to see how many patients achieve a major molecular response (a key sign of disease control) after two years. The goal is to …
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Could a common antibiotic ease Kids' bowel disease?
Disease control Not yet recruitingThis study tests whether oral vancomycin, an antibiotic, can help children aged 6-15 with inflammatory bowel disease (IBD), especially types linked to liver problems. About 140 kids will either get vancomycin plus standard care or standard care alone for up to a year. Researchers…
Phase: PHASE2 • Sponsor: Tampere University Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Engineered t cells target hidden leukemia cells in new trial
Disease control Not yet recruitingThis phase I trial tests a new treatment for adults with acute myeloid leukemia (AML) who have minimal residual disease (MRD) — small amounts of cancer cells that remain after standard therapy. The treatment uses the patient's own T cells, genetically modified to recognize a prot…
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New CAR-T therapy RN9101 targets Hard-to-Treat myeloma
Disease control Not yet recruitingThis early-phase trial tests a new cell therapy called RN9101 in 19 adults with relapsed or refractory multiple myeloma, a blood cancer that has not responded to at least two prior treatments. RN9101 is a type of CAR-T cell therapy given as a single intravenous infusion. The main…
Phase: EARLY_PHASE1 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for aggressive lymphoma: triple-drug combo enters human trials
Disease control Not yet recruitingThis study tests a new combination of drugs for adults with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to previous treatment. About 46 participants will receive an experimental drug (EZH2 inhibitor) along with two other drugs (glofitamab and chemoth…
Phase: PHASE1, PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug cocktail aims to boost transplant success in tough leukemias
Disease control Not yet recruitingThis phase 2 trial tests whether adding two drugs (SHR2554 and azacitidine) to standard chemotherapy before a stem cell transplant can help people with high-risk or relapsed/refractory acute leukemia or myelodysplastic syndromes. About 180 participants aged 15-60 will be randomly…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Could stem cell secretions tame tough Crohn's? new trial aims to find out
Disease control Not yet recruitingThis study tests a new treatment called DB-3Q for people with Crohn's disease that hasn't improved with standard therapies. DB-3Q is made from stem cells and may help reduce inflammation in the gut. The trial will enroll 36 adults and focus on safety and how well the treatment wo…
Phase: PHASE2 • Sponsor: Direct Biologics, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Video Game-Style education could help kids control diabetes
Disease control Not yet recruitingThis study tests whether an interactive educational video, added to standard diabetes education, helps children aged 8 to 14 with type 1 diabetes improve their blood sugar control. The video lets kids make decisions in everyday situations and see the results. Researchers will mea…
Phase: NA • Sponsor: G. d'Annunzio University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combo therapy aims to outsmart leukemia with less poison
Disease control Not yet recruitingThis phase 2 trial is testing a new way to treat adults newly diagnosed with a specific type of acute lymphoblastic leukemia (Ph-negative B-ALL). Instead of standard high-dose chemotherapy, patients receive a mix of low-dose chemo plus several targeted drugs (inotuzumab ozogamici…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Psoriasis patients: does your injection schedule matter?
Disease control Not yet recruitingThis study looks at 120 adults with moderate-to-severe psoriasis who take secukinumab, a biologic drug. It compares two maintenance schedules: the standard every-4-week injection versus a non-standard schedule (longer intervals or lower dose). The goal is to see which schedule ke…
Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Bladder cocktail aims to stop recurrent UTIs in spinal cord injury
Disease control Not yet recruitingThis early study tests whether washing the bladder with an antibiotic (gentamicin) followed by a probiotic (Lactobacillus) can help restore healthy bacteria and prevent urinary tract infections in people with neurogenic bladder due to spinal cord injury, multiple sclerosis, or sp…
Phase: EARLY_PHASE1 • Sponsor: Medstar Health Research Institute • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for tough lymphoma: Three-Drug showdown begins
Disease control Not yet recruitingThis phase II trial tests whether a drug called mosunetuzumab works better alone or combined with either zanubrutinib or polatuzumab vedotin for people with marginal zone lymphoma that has returned or stopped responding to treatment. The study will enroll 138 participants and mea…
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New Sjogren's drug enters first human tests
Disease control Not yet recruitingThis early-stage study tests a new injection called CM336 in 30 adults with active Sjogren's syndrome. The main goal is to check safety and how the body handles the drug. Researchers will also look for signs that it helps control the disease. This is a Phase 1 trial, so it's one …
Phase: PHASE1 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Stem cells take on ankylosing spondylitis: first human trial begins
Disease control Not yet recruitingThis early-phase trial is testing whether stem cells from donated bone marrow (CG-BM1) are safe for people with ankylosing spondylitis, a chronic inflammatory arthritis. Forty adults aged 18 to 40 will receive either the stem cells or a placebo by IV once a week for four weeks. T…
Phase: PHASE1 • Sponsor: Eighth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Automated radiation could make stem cell transplants safer for blood cancer patients
Disease control Not yet recruitingThis trial tests a new automated radiation method that precisely targets bone marrow and lymph nodes before a stem cell transplant. The goal is to kill cancer cells while reducing damage to healthy tissues. Participants have high-risk myeloid cancers like acute myeloid leukemia o…
Phase: PHASE2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New combo aims to wipe out hidden leukemia cells
Disease control Not yet recruitingThis study tests whether adding a new drug called revumenib to the usual treatment (blinatumomab plus chemotherapy) can better clear leftover leukemia cells in people with a specific genetic type of B-cell acute lymphoblastic leukemia (ALL) or mixed-lineage leukemia. About 90 adu…
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New psoriasis cream takes on old standby in Head-to-Head trial
Disease control Not yet recruitingThis study will test whether a newer cream called tapinarof works better than the standard betamethasone cream for mild-to-moderate plaque psoriasis. About 120 adults will use one of the two creams daily for up to 12 weeks. The main goal is to see how many people get at least a 7…
Phase: PHASE4 • Sponsor: Pakistan Institute of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug cocktail targets deadliest blood cancers
Disease control Not yet recruitingThis trial investigates whether adding selinisole to standard chemotherapy drugs (azacitidine and venetoclax) can improve outcomes for people with newly diagnosed, high-risk myeloid tumors that have a TP53 mutation. These tumors are aggressive and hard to treat. The study will me…
Phase: NA • Sponsor: Bing Han • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Engineered immune cells take on aggressive lymphomas in new trial
Disease control Not yet recruitingThis study tests a new treatment called CD70.CAR NK cells for people with diffuse large B-cell lymphoma or Hodgkin lymphoma that did not respond to or came back quickly after initial therapy. The treatment uses specially designed immune cells from a donor to find and attack cance…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
CLL patients may get a break from daily pills
Disease control Not yet recruitingThis study looks at whether people with chronic lymphocytic leukemia (CLL) who have been in remission for at least two years can safely stop taking their BTK inhibitor medication. The goal is to see how long they stay cancer-free without treatment, and whether stopping improves t…
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Engineered immune cells aim to tame stubborn autoimmune diseases
Disease control Not yet recruitingThis early-stage trial tests a one-time infusion of donor immune cells (CAR-γδT cells) designed to target and destroy faulty B cells in people with severe autoimmune diseases like lupus and scleroderma. The main goal is to check safety and find the right dose in 9 adults whose di…
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Radiation and immunotherapy team up against hard-to-treat lymphoma
Disease control Not yet recruitingThis study tests whether giving radiation therapy before the immunotherapy drugs obinutuzumab and glofitamab can improve outcomes for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). About 40 adults who have already tried at least two prior treatments wil…
Phase: PHASE2 • Sponsor: Olivia Newton-John Cancer Research Institute • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for ulcerative colitis patients who failed biologics?
Disease control Not yet recruitingThis study tests an experimental drug called ATH-063 in 120 adults with moderate to severe ulcerative colitis who have not responded to or can no longer use biologic therapies. Participants will receive either the drug or a placebo for 12 weeks to see if it can reduce symptoms an…
Phase: PHASE2 • Sponsor: Athos Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Head-to-Head: which JAK inhibitor tames rheumatoid arthritis best?
Disease control Not yet recruitingThis study will compare two drugs, tofacitinib and upadacitinib, added to standard methotrexate treatment for rheumatoid arthritis. One hundred adults in Pakistan will take one of the two drugs daily for six months. Researchers will measure disease activity and side effects to se…
Phase: PHASE4 • Sponsor: Sheikh Zayed Federal Postgraduate Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New combo aims to tackle Hard-to-Treat leukemia
Disease control Not yet recruitingThis study is testing whether a two-drug combination (venetoclax and azacitidine) followed by a stem cell transplant can help people with a rare, hard-to-treat form of acute myeloid leukemia (AML). The trial will enroll 50 adults who have not been treated before. The goal is to s…
Phase: NA • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New cocktail aims to wake up sleeping HIV
Disease control Not yet recruitingThis early-stage trial tests whether combining two drugs—ibalizumab and chidamide—can safely reduce the hidden HIV reservoir in people living with HIV. The study will enroll up to 29 adults on stable antiretroviral therapy. Researchers will monitor side effects and measure change…
Phase: PHASE1 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for rare blood cancer: targeted drug enters final testing
Disease control Not yet recruitingThis study tests a new drug, INCA033989, against the best current treatments for people with a rare blood cancer called essential thrombocythemia who have a specific gene mutation (CALR). About 426 adults who have already tried at least one prior therapy will be randomly assigned…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug cocktail aims to tame tough leukemias
Disease control Not yet recruitingThis study tests a combination of seven drugs (including asciminib and venetoclax) in 30 adults with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute myeloid leukemia. The first phase checks safety, and the second phase sees if the combo helps control t…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New cell therapy aims to wipe out lingering lymphoma before it returns
Disease control Not yet recruitingThis early-phase trial tests a personalized cell therapy (rapcabtagene autoleucel) in 20 adults with large B-cell lymphoma who still have traces of cancer after initial treatment. The goal is to see if the therapy can make those traces disappear, potentially lowering the risk of …
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Real-World study tracks how long patients stick with gut disease drug
Disease control Not yet recruitingThis study observes 35 adults with moderate-to-severe Crohn's disease or ulcerative colitis to see how long they continue taking guselkumab in everyday medical practice. Researchers will track treatment persistence and early symptom relief, like reduced bowel urgency. No experime…
Sponsor: Janssen-Cilag Pharma GmbH • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Could a monthly pill replace painful penicillin shots for rheumatic heart disease?
Disease control Not yet recruitingThis study will test if taking oral azithromycin pills for three days each month works as well as getting a monthly penicillin shot to prevent rheumatic heart disease from getting worse. The trial plans to enroll 474 Nigerian secondary school students aged 10-18 with mild or mode…
Phase: NA • Sponsor: Ladoke Akintola University of Technology, Ogbomoso, Nigeria • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Can a smartphone app help youth with HIV in the south stick with treatment?
Disease control Not yet recruitingThis study will test a mobile app called MindBodyU designed to help young people (ages 16-25) living with HIV in South Carolina stay connected to their care and take their HIV medication regularly. The goal is to see if the app is easy to use, liked by users, and helps improve me…
Phase: NA • Sponsor: University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New cell therapy takes aim at Hard-to-Treat blood cancers
Disease control Not yet recruitingThis early-stage study tests a new treatment called LVIVO-TaVec122 in 48 adults with B-cell blood cancers that have come back or not responded to standard therapy. The main goals are to check safety, find the right dose, and measure how long the treatment lasts in the body. It is…
Phase: PHASE1 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Can an ancient herbal remedy tame rheumatoid arthritis?
Disease control Not yet recruitingThis study tests whether adding a Chinese herbal formula (Si Miao Xiao Bi Tang) to standard rheumatoid arthritis medication can improve symptoms. About 132 adults with active RA will receive either the herbal medicine or a placebo for 12 weeks. The main goal is to see if more peo…
Phase: PHASE2, PHASE3 • Sponsor: Singapore General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug cevostamab enters early human testing for lupus
Disease control Not yet recruitingThis early-stage trial will test the safety and tolerability of a new drug, cevostamab, in 46 people with systemic lupus erythematosus, some of whom also have active lupus nephritis. The drug is given intravenously, and researchers will monitor side effects and how the drug moves…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New lupus drug tested in kids for first time
Disease control Not yet recruitingThis study tests anifrolumab, a drug already used in adults with lupus, in children aged 5 to 17. The goal is to see how the drug moves through the body and if it is safe. Twenty-four children with moderate to severe lupus will receive the drug as a shot under the skin, while con…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
MS patients switch drugs to save immune defenses
Disease control Not yet recruitingThis study follows 115 adults with multiple sclerosis who are switching from ocrelizumab to ofatumumab because their antibody levels dropped. Researchers want to see if the switch stops or slows that decline over 24 months. The goal is to better manage immune health while still t…
Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New oral drug could tame overactive bone marrow in rare blood cancers
Disease control Not yet recruitingThis study tests a pill called selinexor in 15 adults with chronic blood cancers (MPN) whose blood cell counts are too high. The goal is to see if selinexor can safely bring those counts down and ease symptoms. Participants take the drug once a week for up to 3 months and are fol…
Phase: PHASE2 • Sponsor: Zhongshan Hospital (Xiamen), Fudan University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Ancient gut therapy takes on allergies in new clinical trial
Disease control Not yet recruitingThis study tests whether an Ayurvedic treatment that targets digestion and gut health can reduce allergy symptoms and immune markers in people with allergic rhinitis (hay fever). 104 adults aged 18-40 with confirmed allergies will receive either the Ayurvedic treatment plus stand…
Phase: NA • Sponsor: Amrita Vishwa Vidyapeetham • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New pill could help restore skin color in vitiligo patients
Disease control Not yet recruitingThis study tests an experimental drug called D-2570 in 160 adults with non-segmental vitiligo, a condition that causes white patches on the skin. Participants take either D-2570 or a placebo pill once daily for 24 weeks, with an optional 24-week extension. The goal is to see if t…
Phase: PHASE2 • Sponsor: InventisBio Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Oxygen + light: a new hope for vitiligo repigmentation?
Disease control Not yet recruitingThis study tests whether adding hyperbaric oxygen therapy (breathing pure oxygen in a pressurized chamber) to standard narrowband UVB light treatment can help restore skin color in people with vitiligo. Five adults with non-segmental vitiligo will receive UVB twice a week for 24 …
Phase: PHASE2, PHASE3 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Could a common vitamin a drug tame a deadly immune storm?
Disease control Not yet recruitingThis study tests a drug called all-trans retinoic acid (ATRA) as a first treatment for hemophagocytic lymphohistiocytosis (HLH), a rare but life-threatening condition where the immune system goes into overdrive. ATRA is an oral medication already used for other blood diseases and…
Phase: PHASE2, PHASE3 • Sponsor: Beijing Anzhen Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New targeted radiation therapy aims to improve stem cell transplants for tough myeloma
Disease control Not yet recruitingThis early-phase trial tests a new approach for high-risk multiple myeloma: a radioactive antibody that targets cancer cells, followed by a donor stem cell transplant. The antibody delivers radiation directly to myeloma cells, while chemotherapy and low-dose radiation help prepar…
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for tough leukemia? drug duo targets TP53 mutations
Disease control Not yet recruitingThis early-phase study tests a new drug (ATRN-119) combined with a standard chemotherapy (decitabine) in 27 adults with acute myeloid leukemia or high-risk myelodysplastic syndrome that has a TP53 gene change. The main goals are to find a safe dose and see if the combo can shrink…
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for immunotherapy side effects: blood filtering may replace steroids
Disease control Not yet recruitingThis study tests a treatment called extracorporeal photopheresis (ECP) for people with advanced melanoma who develop severe colitis or hepatitis from immunotherapy. ECP filters a patient's blood, treats it with a light-activated drug, and returns it to the body. The trial compare…
Phase: PHASE2 • Sponsor: Therakos LLC • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New CLL combo aims for Long-Term remission without lifelong pills
Disease control Not yet recruitingThis phase II trial tests a new drug called pirtobrutinib combined with a short course of chemotherapy in 82 fit patients with untreated CLL. The goal is to achieve deep remission with undetectable cancer cells in the blood at 24 months. The treatment lasts only 15 months, aiming…
Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for rare bleeding disorder: experimental drug JCXH-213 enters human trials
Disease control Not yet recruitingThis early-stage study tests a new drug called JCXH-213 in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The trial includes only 4 people whose ITP did not improve with standard treatments. The main goal is to…
Phase: PHASE1 • Sponsor: The General Hospital of Western Theater Command • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for AML patients: experimental drug IPN60340 enters key trial
Disease control Not yet recruitingThis study tests whether adding the experimental drug IPN60340 to standard medicines (azacitidine and venetoclax) helps more people with newly diagnosed acute myeloid leukemia (AML) achieve complete remission. About 450 adults who cannot have intensive chemotherapy will take part…
Phase: PHASE2, PHASE3 • Sponsor: Ipsen • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New cocktail aims to tame myeloma without transplant
Disease control Not yet recruitingThis study tests a combination of four drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) in 88 adults newly diagnosed with multiple myeloma who cannot or choose not to have a stem cell transplant. The goal is to find the safest dose and see how well the drugs control …
Phase: PHASE1, PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New IVIG aims to slash infection risk for immune-deficient patients
Disease control Not yet recruitingThis study tests a new medicine called Boya IVIG in 50 people with primary immunodeficiency (CVID or XLA), a condition where the body can't fight infections well. Participants get the drug every 21 or 28 days for a year to see if it keeps serious bacterial infections below one pe…
Phase: PHASE3 • Sponsor: Azidus Brasil • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug combo aims to tailor myeloma treatment to each patient
Disease control Not yet recruitingThis Phase 3 trial is testing a personalized approach for people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant. After initial treatment with a four-drug combination (isatuximab, iberdomide, bortezomib, and dexamethasone), the next steps—consoli…
Phase: PHASE3 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New 'Off-the-Shelf' CAR-T therapy takes on Hard-to-Treat myeloma
Disease control Not yet recruitingThis early-phase trial is testing DQ1001, a ready-made CAR-T cell therapy that targets two proteins (BCMA and GPRC5D) on myeloma cells. It is designed for patients whose multiple myeloma has returned or stopped responding to at least three prior treatments. The study will enroll …
Phase: PHASE1 • Sponsor: Zhongshan Hospital (Xiamen), Fudan University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Experimental CAR-T therapy targets tough childhood blood cancers
Disease control Not yet recruitingThis early-phase trial is testing a new treatment called PA3-17 injection for children and teens aged 3 to 18 with T-cell leukemia or lymphoma that has not responded to standard therapy or has come back. The treatment uses the patient's own immune cells, modified to recognize and…
Phase: PHASE1 • Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for multiple myeloma: phase 3 trial launches
Disease control Not yet recruitingThis Phase 3 trial tests a new drug called IBI3003 against standard treatments for people with multiple myeloma that has returned or is not responding to therapy. About 255 participants will be randomly assigned to receive either IBI3003 or a standard treatment chosen by their do…
Phase: PHASE3 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug aims to keep lymphoma in check after CAR-T treatment
Disease control Not yet recruitingThis study tests whether the drug pirtobrutinib can help prevent relapse in people with B-cell lymphoma who have already received CAR-T cell therapy. Twenty adults will take pirtobrutinib daily for six months after their CAR-T infusion. The main goal is to see how many achieve a …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could licorice root make CAR-T cancer therapy safer and stronger?
Disease control Not yet recruitingThis study tests whether a compound from licorice root, called diammonium glycyrrhizinate, can reduce the toxic side effects and improve the cancer-killing power of CAR-T cell therapy in people with large B-cell lymphoma. About 21 participants will receive either standard care or…
Phase: PHASE2, PHASE3 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug aims to stop IgG4 disease relapses without Long-Term steroids
Disease control Not yet recruitingThis study tests a drug called IMM0306 in 125 people with IgG4-related disease, a condition where the immune system attacks organs causing swelling and damage. The goal is to see if IMM0306 can prevent disease flare-ups and allow patients to safely stop taking steroids. Participa…
Phase: PHASE2, PHASE3 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
HIV cocktail aims to free patients from daily pills
Disease control Not yet recruitingThis phase 2 trial tests whether a mix of intensified antiretrovirals, a latency-reversing drug, an anti-proliferative drug, and a personalized vaccine can shrink the hidden HIV reservoir enough to allow people to stop their daily medication. The study will enroll 70 adults with …
Phase: PHASE2 • Sponsor: Federal University of São Paulo • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill may boost insulin pump performance in type 1 diabetes
Disease control Not yet recruitingThis study tests an experimental pill (cadisegliatin) taken alongside insulin in people with type 1 diabetes who already use a hybrid closed-loop insulin pump. The goal is to see if the pill helps keep blood sugar in a healthy range more consistently. About 40 adults will receive…
Phase: PHASE2 • Sponsor: vTv Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug aims to ease anemia in bone marrow cancer patients
Disease control Not yet recruitingThis Phase 3 trial tests whether elritercept can improve anemia in people with myelofibrosis who are already taking ruxolitinib. About 324 participants will receive either elritercept or a placebo for at least 9 months. The main goal is to see if the drug reduces the need for red…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for myasthenia gravis patients: experimental drug enters phase 2 trial
Disease control Not yet recruitingThis study tests whether SHR-2173, added to usual care, improves symptoms of generalized myasthenia gravis (gMG) better than a placebo. About 60 adults with confirmed gMG will receive the drug or placebo for 24 weeks. The main goal is to see if daily muscle weakness and fatigue s…
Phase: PHASE2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill takes on tough blood cancers in first human trial
Disease control Not yet recruitingThis early-stage study tests a new tablet, FXS0683, in 228 adults with blood cancers like lymphoma or leukemia that returned or didn't respond to standard therapy. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will be clo…
Phase: PHASE1 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Can a shingles vaccine and diabetes drug save insulin cells?
Disease control Not yet recruitingThis study tests whether the shingles vaccine Shingrix and the diabetes drug semaglutide, alone or together, can help preserve the body's ability to make insulin in adults recently diagnosed with type 1 diabetes. The goal is to slow the immune attack on insulin-producing cells an…
Phase: PHASE2 • Sponsor: Ministry of Health, Saudi Arabia • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Migraine drug may boost CAR-T therapy in tough lymphoma
Disease control Not yet recruitingThis Phase 2 trial tests whether adding the migraine drug rimegepant to a standard CAR-T cell therapy and another immunotherapy (glofitamab) can improve outcomes for people with high-risk relapsed or refractory large B-cell lymphoma. About 100 adults will be randomly assigned to …
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Experimental CAR-T injection aims to tame autoimmune diseases
Disease control Not yet recruitingThis early-phase trial tests an injection called KSVCBD, a type of CAR-T cell therapy, in 60 adults with severe autoimmune diseases like lupus and scleroderma. The goal is to see if it's safe and to get a first look at whether it might help control the disease. Participants recei…
Phase: EARLY_PHASE1 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a common gout drug ease thyroid inflammation?
Disease control Not yet recruitingThis study tests whether low-dose colchicine, a drug used for gout, can reduce inflammation and symptoms in people with autoimmune or subacute thyroiditis. About 300 adults will be randomly assigned to colchicine, corticosteroids, or supportive care. The goal is to see if colchic…
Phase: PHASE2, PHASE3 • Sponsor: Mansoura University • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New MS biosimilar PB018 faces first human test against ocrevus
Disease control Not yet recruitingThis Phase 1 trial will test PB018, a biosimilar to the MS drug Ocrevus, in 222 people with multiple sclerosis. The study compares how the body processes PB018 versus Ocrevus and checks for safety. Participants will receive either PB018 or Ocrevus, but neither they nor their doct…
Phase: PHASE1 • Sponsor: Polpharma Biologics International AG • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New CAR T-Cell therapy targets Hard-to-Treat myeloma
Disease control Not yet recruitingThis early-stage trial tests the safety of a new CAR T-cell therapy, UF-KURE-BCMA, in 12 adults with multiple myeloma that has returned or not responded to other treatments. The therapy uses specially engineered immune cells to target and attack cancer cells. The main goal is to …
Phase: PHASE1 • Sponsor: Kure Cells, INC • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
In-Body CAR-T: a new shot at fighting blood cancers?
Disease control Not yet recruitingThis early study tests a new treatment called U96 for people with B-cell leukemia or lymphoma that has come back or not responded to standard therapy. U96 is a gene therapy given as a single infusion that aims to create cancer-fighting CAR-T cells inside the patient's own body. T…
Phase: PHASE1 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Could a 3-Step immune therapy save Insulin-Making cells in newly diagnosed type 1 diabetes?
Disease control Not yet recruitingThis early-phase trial tests a three-step immune treatment for people recently diagnosed with Type 1 diabetes (within 6 months). The goal is to preserve the body's remaining insulin production by calming the immune attack and teaching the immune system to tolerate insulin. Sixty …
Phase: PHASE1 • Sponsor: Abdullah Kars • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Can a Pre-Dose prevent a dangerous reaction in multiple myeloma treatment?
Disease control Not yet recruitingThis study tests whether giving tocilizumab before the first dose of linvoseltamab can lower the risk of cytokine release syndrome (CRS) in people with relapsed or refractory multiple myeloma. The 30 participants have already tried at least four prior treatments. Researchers will…
Phase: PHASE4 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
MS patients may soon get a simpler shot option
Disease control Not yet recruitingThis study looks at whether people with multiple sclerosis can safely switch from their current anti-CD20 therapy to a new under-the-skin version of ocrelizumab. About 100 participants will be followed for up to 48 weeks to see if brain lesions stay stable and if they are satisfi…
Phase: PHASE4 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Experimental pill plus chemo takes aim at Hard-to-Treat brain lymphoma
Disease control Not yet recruitingThis early-phase trial tests a new oral drug called golcadomide combined with standard chemotherapy drugs (pemetrexed, rituximab, and dexamethasone) in 18 adults with large B-cell lymphoma that has spread to the brain or central nervous system and has either returned or is not re…
Phase: PHASE1 • Sponsor: Allison Winter • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New cocktail aims to tame Slow-Growing blood cancers
Disease control Not yet recruitingThis Phase II trial will test a combination of pomalidomide, an anti-CD20 antibody, and prednisone as a first treatment for people with indolent (slow-growing) B-cell lymphomas. About 30 adults who have not had prior therapy will receive six cycles of the combo, followed by two y…
Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug STR-P005 aims to tame stubborn autoimmune diseases
Disease control Not yet recruitingThis early study tests a new drug called STR-P005 in 18 people with autoimmune diseases that have not responded to standard treatments. The main goal is to check safety and find the best dose. Participants receive the drug by infusion in different schedules, and researchers will …
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
AI helps target stomach cancer with less harm to healthy organs
Disease control Not yet recruitingThis study tests a new way to deliver radiation for gastric MALT lymphoma. Using AI, the treatment adapts each session to better protect nearby organs. About 25 adults with early-stage disease will take part. The goal is to see if this approach is safe and effective.
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for rare blood cancer: QUANTUM trial tests targeted therapy after transplant
Disease control Not yet recruitingThis study tests whether a new drug called teclistamab, given after standard treatment and a stem cell transplant, can help people with a rare and aggressive blood cancer called plasma cell leukemia live longer. About 74 participants will receive either standard follow-up therapy…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for lymphoma patients when CAR-T fails: tailored drug cocktail shows promise
Disease control Not yet recruitingThis study tests a personalized treatment approach for people with large B-cell lymphoma whose cancer did not respond to CAR-T cell therapy. Researchers will analyze the tumor's surrounding environment to classify it into one of four subtypes, then give patients a drug combinatio…
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New injection shows promise for Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…
Phase: PHASE1 • Sponsor: Jecho Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Engineered immune cells take on rare blood disorders
Disease control Not yet recruitingThis phase 2 trial tests a personalized CAR T cell therapy called zolacabtagene autoleucel in 52 adults with chronic immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA). The treatment uses the patient's own immune cells, modified to target and destroy faulty B cel…
Phase: PHASE2 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Can a Two-Dose drug delay type 1 diabetes as well as a 14-Day treatment?
Disease control Not yet recruitingThis study compares two drugs, ATG and teplizumab, to see if they can delay or prevent type 1 diabetes in people who are at high risk. About 60 participants aged 4 to 35 will receive either two infusions of ATG or 14 daily infusions of teplizumab. Researchers will monitor them fo…
Phase: PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug combo aims to tame stubborn blood disorders
Disease control Not yet recruitingThis early-phase study tests whether combining two drugs (Zuberitamab and Orelabrutinib) can help people with immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA) that hasn't responded to other treatments. The drugs work together to calm the immune system and stop …
Phase: PHASE1 • Sponsor: Qi deng • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Gene therapy could replace bone marrow transplants for rare immune disease
Disease control Not yet recruitingThis trial tests a gene therapy for FHL3, a rare immune disorder caused by a gene mutation. Instead of a donor stem cell transplant, patients receive their own stem cells that have been corrected with a healthy gene. The goal is to restore immune function while avoiding transplan…
Phase: PHASE1, PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New hope for relapsed blood cancer: Three-Drug combo enters trials
Disease control Not yet recruitingThis study tests a new combination of three drugs (lisaftoclax, chidamide, and rituximab) in adults with a type of blood cancer called diffuse large B-cell lymphoma that has come back or not responded to prior treatment. The goal is to find a safe and effective dose and see if th…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Poop pills or tubes: could fecal transplants tame deadly transplant complication?
Disease control Not yet recruitingThis study tests whether giving fecal microbiota (from a healthy donor) via a tube or scope into the gut can safely help children and young adults with severe intestinal graft-versus-host disease that hasn't improved with steroids. About 20 participants aged 3 months to 25 years …
Phase: PHASE1, PHASE2 • Sponsor: Bambino Gesù Hospital and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New app aims to help black adults with HIV kick the habit and ease anxiety
Disease control Not yet recruitingThis study tests a smartphone app called ESCAPE, designed specifically for Black adults with HIV who smoke. The app teaches ways to handle stress, anxiety, and nicotine cravings, and is paired with nicotine patches or gum. 300 participants across the US will be randomly assigned …
Phase: PHASE2 • Sponsor: University of Houston • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New eczema cream shows promise in major trial
Disease control Not yet recruitingThis study tests a new cream called VC005 for people aged 12 and older with mild to moderate atopic dermatitis (eczema). The goal is to see if the cream can clear or nearly clear the skin rash better than a cream without medicine. About 360 participants will use either the study …
Phase: PHASE3 • Sponsor: Jiangsu vcare pharmaceutical technology co., LTD • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Could a High-Protein, High-Fiber diet tame ulcerative colitis?
Disease control Not yet recruitingThis study will test whether a diet rich in protein and fiber can reduce harmful gas-producing bacteria in the gut of people with ulcerative colitis. Forty adults with mild to moderate disease will eat specially prepared frozen meals for two separate week-long periods. Researcher…
Phase: NA • Sponsor: University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for young leukemia patients: experimental drug combo targets resistant cancer
Disease control Not yet recruitingThis study tests a new drug called asciminib, given with chemotherapy and later with another drug (blinatumomab), in children, teens, and young adults up to age 30 who have a type of leukemia (Ph+ or Ph-like ALL) that has come back or not responded to treatment. The goal is to fi…
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New shot could help thyroid patients who Don't respond to usual pills
Disease control Not yet recruitingThis study tests an investigational drug called efgartigimod for adults with Graves' disease whose thyroid levels are still high despite taking standard antithyroid medications. About 230 participants will receive either the drug or a placebo as a shot under the skin. The goal is…
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New insulin algorithm aims to simplify diabetes management
Disease control Not yet recruitingThis study tests a next-generation automated insulin delivery system (Omnipod M) in up to 40 adults with type 1 diabetes. The goal is to see if the system safely improves blood sugar control by reducing dangerously low and high levels. Participants will use the device during hote…
Phase: NA • Sponsor: Insulet Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
AI takes on lymphoma: personalized treatment strategy under trial
Disease control Not yet recruitingThis study compares an AI-driven treatment strategy to standard therapy (Pola-R-CHP) for people with previously untreated large B-cell lymphoma. About 178 participants will be grouped by risk using an AI model, and those at intermediate or high risk will receive either a personal…
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New MS drug trial uses Super-Powered MRI to see inside the brain
Disease control Not yet recruitingThis study tests an experimental drug called remibrutinib in 20 people with relapsing or progressive multiple sclerosis (MS). Participants take the drug twice daily for 2 years and undergo powerful 7T MRI scans to measure changes in brain volume, lesions, and tissue health. The g…
Phase: PHASE2 • Sponsor: Moein Amin • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New cream could help kids with vitiligo regain skin color
Disease control Not yet recruitingThis study tests a cream called ruxolitinib on children aged 2 to 11 with a common type of vitiligo (white patches on skin). The goal is to see if the cream can safely bring back skin color over 24 weeks. About 20 children will apply the cream daily and visit the clinic for check…
Phase: PHASE3 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New trial aims to match diabetes drugs to patients for better heart and kidney protection
Disease control Not yet recruitingThis phase 2 trial will test two drugs, finerenone and sotagliflozin, in 57 people with type 1 diabetes who are at risk for heart and kidney problems. The goal is to see if matching the right drug to each person's specific diabetes subtype can improve early signs of heart and kid…
Phase: PHASE2 • Sponsor: Oregon Health and Science University • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Diabetes drug tirzepatide tested for type 1 in new trial
Disease control Not yet recruitingThis study tests whether tirzepatide, a drug used for type 2 diabetes, can help people with type 1 diabetes. Researchers will measure how the body responds to insulin and meals before and after 6 weeks of treatment. 44 adults with type 1 diabetes who use an automated insulin pump…
Phase: PHASE2 • Sponsor: Victor Chang Cardiac Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for lymphoma patients: glofitamab combo faces standard care in trial
Disease control Not yet recruitingThis study tests whether adding the immunotherapy drug glofitamab to standard chemotherapy (gemcitabine and oxaliplatin) works better than usual treatments for people with large B-cell lymphoma that has returned or not responded to first therapy. About 96 adults will be randomly …
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New 5-Drug cocktail aims to tackle High-Risk myeloma
Disease control Not yet recruitingThis study tests a new five-drug combination for people newly diagnosed with a high-risk form of multiple myeloma. The drugs include etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The trial will enroll 220 participants and first check safety, then see if the …
Phase: PHASE1, PHASE2 • Sponsor: Universitätsklinikum Hamburg-Eppendorf • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Can a vitamin a drug boost platelets in Hard-to-Treat ITP?
Disease control Not yet recruitingThis study tests all-trans retinoic acid (ATRA), a form of vitamin A, in adults with immune thrombocytopenia (ITP) whose platelet counts stay low despite steroid treatment. About 192 participants will receive either ATRA or a placebo for 24 weeks. The goal is to see if ATRA can s…
Phase: PHASE3 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for older AML patients: gentler transplant approach aims to boost survival with less toxicity
Disease control Not yet recruitingThis study tests a reduced-intensity chemotherapy combination (fludarabine and treosulfan) before a half-matched stem cell transplant in 77 older or frail adults with AML. The goal is to see if this gentler regimen can control the leukemia long-term while being safe enough for pa…
Phase: PHASE2 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Off-the-Shelf CAR-Ts take on lupus and more
Disease control Not yet recruitingThis early-phase trial tests a single dose of universal (off-the-shelf) CAR-T cells in 30 adults with active autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's. The treatment targets CD19 and BCMA on immune cells to reset the faulty immune system. The…
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug aims to tame autoimmune hepatitis and cut steroid use
Disease control Not yet recruitingThis study tests a drug called inebilizumab in 180 adults with autoimmune hepatitis, a condition where the immune system attacks the liver. The goal is to see if the drug can reduce liver inflammation and allow patients to take lower doses of steroids. Participants will receive e…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Smart patch may replace finger sticks for hospital insulin dosing
Disease control Not yet recruitingThis study will test whether a continuous glucose monitor (CGM) can safely guide insulin therapy in cancer and transplant patients who are not in the ICU but need IV insulin due to steroids and nutrition. About 80 participants will be randomly assigned to CGM-guided care or stand…
Phase: NA • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Engineered immune cells take on Hard-to-Treat myeloma
Disease control Not yet recruitingThis early-phase study tests a new kind of CAR T-cell therapy for people with multiple myeloma that has come back or not responded to at least three prior treatments. The cells are 'armored' to resist a protein (TGF-beta) that normally blocks their attack. Up to 30 adults will re…
Phase: PHASE1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for tough leukemia: experimental drug PLM-102 enters first human tests
Disease control Not yet recruitingThis early-phase study tests a new drug called PLM-102 in 12 adults whose acute myeloid leukemia (AML) has come back or not responded to standard treatments. The main goals are to find the highest safe dose and to monitor side effects. Participants must have relapsed or refractor…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New PET tracer aims to reveal hidden myeloma spots
Diagnosis Not yet recruitingThis study tests a new radioactive tracer for PET/CT scans that targets a protein called GPRC5D found on multiple myeloma cells. About 50 adults with plasma cell disorders, including multiple myeloma, will receive the tracer and then undergo imaging. The goal is to see if this me…
Phase: PHASE1 • Sponsor: Peking University First Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 14:01 UTC
-
Ultrasound may solve arthritis diagnosis puzzle
Diagnosis Not yet recruitingRheumatoid arthritis and gout can look alike, making them hard to tell apart early. This study will use ultrasound to see if it can reliably distinguish between the two conditions. Researchers will examine 100 adults with suspected or confirmed arthritis, scoring joint inflammati…
Sponsor: Assiut University • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
New Pill-Sized device could prevent dangerous blockages during gut scans
Diagnosis Not yet recruitingThis study tests a special capsule that patients swallow to check if their intestines are clear enough for a standard camera capsule. About 25 people with known or suspected intestinal narrowing will take part. They will swallow the patency capsule and get an X-ray within 30 hour…
Phase: NA • Sponsor: AnX Robotica Corp. • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Painless blood test could replace bone marrow biopsy for MPN patients
Diagnosis Not yet recruitingThis study aims to develop a new blood test that could replace the invasive bone marrow biopsy currently used to diagnose myeloproliferative neoplasms (MPNs), a group of blood cancers. Researchers will collect blood samples from 500 adults with suspected or confirmed MPN and anal…
Sponsor: Weizmann Institute of Science • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Urine test may replace colonoscopy for colitis patients
Diagnosis Not yet recruitingThis study looks at whether a substance in urine, called PGE-MUM, can show if ulcerative colitis is active or in remission. Researchers will collect urine and blood samples from 114 adults with confirmed ulcerative colitis and compare the results with colonoscopy findings. If suc…
Sponsor: Assiut University • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
New scan aims to tell two types of hand arthritis apart
Diagnosis Not yet recruitingThis study tests a special imaging agent (99mTc-NTP 15-5) to see if it can spot arthritis-damaged joints in the hands and tell the difference between osteoarthritis and rheumatoid arthritis. About 80 adults with one of these conditions will get a scan. The goal is to improve diag…
Phase: PHASE2 • Sponsor: Centre Jean Perrin • Aim: Diagnosis
Last updated Jun 27, 2026 13:03 UTC
-
AI tool aims to cut allergy misdiagnosis in primary care
Diagnosis Not yet recruitingThis study tests whether AI-powered decision trees can help general practitioners better diagnose and manage allergies. About 600 patients with suspected allergies will be enrolled, and doctors will use an app that suggests next steps based on symptoms. The goal is to see if this…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Diagnosis
Last updated Jun 27, 2026 13:02 UTC
-
Modified pork could revolutionize Alpha-Gal allergy testing
Diagnosis Not yet recruitingThis study tests whether specially modified pork (alpha-gal knockout) causes fewer allergic reactions than regular pork in people with alpha-gal syndrome. Each of the 160 participants will eat both types of pork on different days to see which one is safer for diagnosis. The goal …
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
New scan spots hidden organ damage before symptoms start
Diagnosis Not yet recruitingThis study explores whether a PET/MR scan using a radioactive tracer called 18F-Florbetaben can detect amyloid deposits—abnormal protein clumps that can damage organs—in people with certain blood disorders. Participants receive a single injection of the tracer followed by a whole…
Phase: NA • Sponsor: University of Zurich • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
Could a stool sample replace a spinal tap? new study tests Non-Invasive infection detection
Diagnosis Not yet recruitingThis study will test whether analyzing stool and urine samples using a technique called metagenomics can find infections in people with weakened immune systems (due to HIV, chemotherapy, or immunosuppressive drugs). Currently, doctors often need to take invasive samples like bloo…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Diagnosis
Last updated Jun 27, 2026 12:36 UTC
-
Ultrasound may spare breast cancer patients unnecessary surgery
Diagnosis Not yet recruitingThis study looks at whether a special ultrasound can accurately detect if breast cancer has completely disappeared from lymph nodes after chemotherapy. About 150 women with cancer that spread to their lymph nodes will have a small clip placed in a cancerous node before treatment.…
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Diagnosis
Last updated Jun 27, 2026 12:35 UTC
-
New drug aims to stop deadly complication in leukemia therapy
Prevention Not yet recruitingThis study tests whether the drug Lisaftoclax can prevent differentiation syndrome (DS), a severe and sometimes life-threatening side effect, in people with acute promyelocytic leukemia (APL) who are receiving standard treatment. About 60 participants aged 16 and older will take …
Phase: PHASE2, PHASE3 • Sponsor: The Affiliated People's Hospital of Ningbo University • Aim: Prevention
Last updated Jul 02, 2026 00:00 UTC
-
Light therapy may shield kids with cancer from chemo mouth sores
Prevention Not yet recruitingThis study tests whether light therapy (photobiomodulation) can prevent mouth sores in children receiving chemotherapy. Fifty children aged 0-30 will receive daily light treatments during hospital stays and at home. Researchers will check if the therapy is easy to use and accepta…
Phase: NA • Sponsor: Medical College of Wisconsin • Aim: Prevention
Last updated Jun 27, 2026 14:01 UTC
-
Double probe heat therapy may slash cervical cancer risk in HIV-positive women
Prevention Not yet recruitingThis study will test if using two heat probes instead of one can better prevent cervical cancer in 300 women with HIV in Zimbabwe. The standard single-probe treatment often fails in these women. The goal is to see if the two-probe method is safe, acceptable, and more effective at…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 13:08 UTC
-
New probe technique could slash cervical cancer risk in HIV-Positive women
Prevention Not yet recruitingThis study tests whether using two probes during a heat-based treatment (thermal ablation) works better than the usual one-probe method to prevent cervical cancer in women living with HIV. About 200 women aged 25-49 with HIV and cervical precancer will be enrolled. The goal is to…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
Village health workers lead new HIV prevention effort in lesotho
Prevention Not yet recruitingThis study tests a new program where trained village health workers use tablet-based tools to provide HIV prevention services, including PrEP and emergency PEP, to people at high risk in rural Lesotho. About 380 participants will be enrolled to see if this approach increases mont…
Phase: NA • Sponsor: University Hospital, Basel, Switzerland • Aim: Prevention
Last updated Jun 27, 2026 12:37 UTC
-
Could a simple supplement boost knee injection results for arthritis sufferers?
Symptom relief Not yet recruitingThis study tests whether adding an oral supplement (PEA) to a series of knee injections (adelmidrol and hyaluronic acid) can better reduce pain and improve function in people with knee arthritis. The injections aim to protect the joint from damage, while the supplement may help c…
Phase: NA • Sponsor: Universita di Verona • Aim: Symptom relief
Last updated Jul 04, 2026 00:00 UTC
-
Can a smartphone app help tame IBD symptoms?
Symptom relief Not yet recruitingThis pilot study will test a 24-week digital self-management program designed to help people with inflammatory bowel disease (IBD) manage their symptoms and build long-term healthy habits. The program is accessed via web or mobile device and is used alongside standard care. The s…
Phase: NA • Sponsor: University of Michigan • Aim: Symptom relief
Last updated Jul 04, 2026 00:00 UTC
-
New injection could tame teen hay fever
Symptom relief Not yet recruitingThis study tests whether an injection called stapokibart can reduce nasal allergy symptoms like runny nose, congestion, sneezing, and itching in adolescents aged 12 to 17 with seasonal allergic rhinitis (hay fever). Participants receive either stapokibart or a placebo alongside t…
Phase: PHASE3 • Sponsor: Chengdu Kangnuoxing Biopharma,Inc. • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
AI coach for parents of diabetic kids: will it make carb counting easier?
Symptom relief Not yet recruitingThis study tests whether an AI-powered educational platform can help parents of children with type 1 diabetes count carbohydrates more accurately and manage diabetes better. About 80 parents will either use the AI platform plus usual care or usual care alone for 12 weeks. The goa…
Phase: NA • Sponsor: Sultan Qaboos University • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
New study tests which laser technique clears kidney stones faster
Symptom relief Not yet recruitingThis study compares two ways to break up kidney stones using a laser and a suction device. One method turns stones into dust, the other into small fragments. The goal is to see which leaves fewer stone pieces behind after one month. About 86 adults with small kidney stones will t…
Phase: NA • Sponsor: Bir Hospital • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Experimental antibodies aim to block cat allergy eye itch
Symptom relief Not yet recruitingThis study tests whether two experimental antibodies, given alone or together, can reduce eye allergy symptoms caused by cat dander. About 570 adults and children aged 8 and older with confirmed cat allergy will receive either the antibodies or a placebo. The main goal is to see …
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Hypnosis as a hospital treatment for gut disorders?
Symptom relief Not yet recruitingThis pilot study compares recorded gut-directed hypnosis to an educational recording for hospitalized patients with chronic gut problems, such as irritable bowel syndrome or inflammatory bowel disease. Participants listen to the recordings over the phone while in the hospital for…
Phase: NA • Sponsor: Stanford University • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Can a 2-Hour online class ease IBD pain?
Symptom relief Not yet recruitingThis study tests two online pain education programs for adults with Crohn's disease or ulcerative colitis who have chronic pain. Participants will complete a 2-hour online session and report their pain and quality of life weekly for 8 weeks. The goal is to see if these programs a…
Phase: NA • Sponsor: Cedars-Sinai Medical Center • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
New CGM training program aims to help seniors with diabetes
Symptom relief Not yet recruitingThis study tests a three-session training program to help older adults (65+) who use insulin learn to use a continuous glucose monitor (CGM). Participants will be randomly assigned to the program or standard training. The goal is to see if the program improves how often they wear…
Phase: NA • Sponsor: University of North Carolina, Chapel Hill • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
AI-Powered diet advice could help cancer patients eat better during treatment
Symptom relief Not yet recruitingThis study tests whether an AI-based website that gives personalized diet tips and recipes can help cancer patients who experience taste changes during therapy. About 198 adults with certain cancers (like multiple myeloma, melanoma, or GI cancers) will either get the AI tool or a…
Phase: NA • Sponsor: Wuerzburg University Hospital • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Puzzle power: activity book aims to boost insulin skills in diabetic kids
Symptom relief Not yet recruitingThis study tests whether an activity book called 'Think-Find-Solve' can improve insulin self-management in children aged 8-12 with type 1 diabetes. Forty children and their parents will take part, with one group using the book for three months. The goal is to see if the book help…
Phase: NA • Sponsor: Marmara University • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Can a phone app help RA patients feel less anxious?
Symptom relief Not yet recruitingThis study tests whether an 8-week program of yoga and meditation delivered through a mobile app can reduce anxiety in adults with stable rheumatoid arthritis. About 100 participants will either use the app daily or continue with standard care. Researchers will measure changes in…
Phase: NA • Sponsor: Tugba Civi Karaaslan • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
Could a bone drug ease pain in kids with rare inflammatory disease?
Symptom relief Not yet recruitingThis study tests whether the drug zoledronate can reduce pain in children aged 4 to 17 with chronic recurrent multifocal osteomyelitis (CRMO), a rare auto-inflammatory bone disease. The 30 participants have not responded to standard anti-inflammatory drugs. They will receive eith…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
New rehab combo aims to ease MS fatigue and boost brain function
Symptom relief Not yet recruitingThis study tests whether a 12-week program combining individual physiotherapy, group movement-awareness sessions, and group psychotherapy can improve physical function, reduce fatigue, and enhance quality of life in 45 adults with multiple sclerosis. Each participant serves as th…
Phase: NA • Sponsor: Charles University, Czech Republic • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Could a simple infusion after bowel surgery cut opioid use and speed recovery?
Symptom relief Not yet recruitingThis study tests whether giving a drug called dexmedetomidine for 48 hours after laparoscopic bowel surgery helps patients recover better. About 70 adults will receive either the drug or a placebo, and neither they nor their doctors will know which. The main goal is to see if the…
Phase: PHASE3 • Sponsor: Dr. Naveed Siddiqui • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Can a smartphone app ease the Gut-Brain struggle for IBD patients?
Symptom relief Not yet recruitingThis study tests a mobile app designed to help Black and Hispanic adults with inflammatory bowel disease (IBD) manage stress and improve their quality of life. The app teaches coping skills, mindfulness, and disease acceptance. Researchers want to see if the app is practical and …
Phase: NA • Sponsor: Montefiore Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New injection aims to ease breathing in cancer patients with Fluid-Filled lungs
Symptom relief Not yet recruitingThis study tests a new drug, JMKX000197, against a standard chemotherapy drug (cisplatin) to see which works better at controlling fluid buildup around the lungs in people with advanced cancer. About 120 participants with moderate to large fluid collections will receive the drug …
Phase: PHASE2 • Sponsor: Shanghai Jeyou Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Could electromagnetic pulses help MS patients stay steady?
Symptom relief Not yet recruitingThis study tests whether a device that delivers high-intensity focused electromagnetic pulses can strengthen core muscles and improve balance in people with multiple sclerosis. Sixty participants will either receive the electromagnetic therapy plus balance exercises, or balance e…
Phase: NA • Sponsor: Middle East University • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New foam aims to soothe immunotherapy skin side effects
Symptom relief Not yet recruitingThis phase 2 trial tests a medicated foam called roflumilast on skin rashes caused by checkpoint inhibitor cancer drugs. Twenty adults with mild to severe rash will apply the foam daily for 16 weeks. The goal is to see if it safely reduces rash severity and improves quality of li…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Nurse-Led video calls aim to empower MS patients
Symptom relief Not yet recruitingThis study tests a six-month personalized telenursing program for 110 adults with multiple sclerosis. Participants receive monthly educational videos and nurse-led video calls to help them better understand their health and navigate the healthcare system. The goal is to improve h…
Phase: NA • Sponsor: G. d'Annunzio University • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Exercise during chemo: new study tests strength training for children with leukemia
Symptom relief Not yet recruitingThis study tests whether a 9-week strength training program using resistance bands and body weight exercises is practical for children aged 6-21 newly diagnosed with acute lymphoblastic leukemia or lymphoblastic lymphoma. The program combines at-home exercises with optional Zoom …
Phase: NA • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
New hope for stiff person syndrome: drug trial aims to ease muscle stiffness and improve walking
Symptom relief Not yet recruitingThis study tests a medicine called IGIV 10% (a type of antibody treatment) against a placebo in 38 adults aged 18-70 with Stiff Person Syndrome, a rare condition causing muscle stiffness and spasms. The main goal is to see if the drug helps people walk faster (measured by a 25-fo…
Phase: PHASE3 • Sponsor: Kedrion S.p.A. • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
Can a special diet tame ulcerative colitis? breath tests may tell
Symptom relief Not yet recruitingThis study tests whether a short liquid diet followed by a low-sulfur eating plan is safe and helpful for people with mild to moderate ulcerative colitis. Researchers will check if this approach improves gut health, lowers inflammation, and eases symptoms. They will also use brea…
Phase: NA • Sponsor: University of British Columbia • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Can computer games clear the fog? new study tests brain training for ME/CFS
Symptom relief Not yet recruitingThis study compares two brain-training programs for adults with ME/CFS who experience brain fog. Both programs include computer games and a mild nerve stimulation device, but one focuses on processing speed and daily tasks while the other emphasizes relaxation and healthy habits.…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Tailored video chats aim to boost exercise confidence in type 1 diabetes
Symptom relief Not yet recruitingThis study tests whether individualized video consultations can help adults with type 1 diabetes manage exercise and blood sugar more confidently. Sixty participants will receive up to three 30-minute sessions with a doctor or exercise specialist. The goal is to improve self-mana…
Phase: NA • Sponsor: University of Aarhus • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Could Low-Oxygen breathing supercharge gait therapy for MS?
Symptom relief Not yet recruitingThis study tests whether breathing low-oxygen air for short periods right before walking training helps people with multiple sclerosis walk better and farther. Thirty-five participants will receive either the low-oxygen breathing or a sham (placebo) version, followed by treadmill…
Phase: NA • Sponsor: Shirley Ryan AbilityLab • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Salt shaker showdown: could less sodium mean less eczema itch?
Symptom relief Not yet recruitingThis study looks at whether lowering salt in your diet can make eczema less severe. Forty adults with eczema will eat a low-salt diet for 24 weeks. For 5 weeks they'll take salt pills, and for another 5 weeks they'll take placebo pills, to see the real effect of sodium. Researche…
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
New online program aims to lift depression in MS patients
Symptom relief Not yet recruitingThis study tests whether an internet-based program called My MS Toolkit can help reduce depression in people with multiple sclerosis. The toolkit teaches skills based on cognitive behavioral therapy to manage common MS symptoms like fatigue, pain, and low mood. Researchers will c…
Phase: NA • Sponsor: University of Washington • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Could a common drug ease psoriasis? new study seeks answers
Symptom relief Not yet recruitingThis study tests whether adding a pill called pentoxifylline to standard skin creams can improve mild-to-moderate psoriasis. About 140 adults will take either the study drug or a placebo twice daily for 12 weeks. Researchers will measure changes in skin severity, itch, and qualit…
Phase: NA • Sponsor: Wasuchon Chaichan • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Myeloma patients may soon skip hospital trips by Self-Injecting at home
Symptom relief Not yet recruitingThis study looks at whether people with multiple myeloma can safely give themselves the drug daratumumab at home instead of going to the hospital. About 50 patients will take turns receiving the injection at home and at the clinic to compare the two approaches. The goal is to see…
Phase: PHASE4 • Sponsor: Odense University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
Could brief low-oxygen sessions help MS? small safety trial launches
Symptom relief Not yet recruitingThis early-stage study tests whether short periods of breathing low-oxygen air (called acute intermittent hypoxia) are safe and tolerable for people with multiple sclerosis. Nine participants at different disease stages will be closely monitored for side effects like low oxygen l…
Phase: PHASE1, PHASE2 • Sponsor: University of Saskatchewan • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Sound waves could ease chronic leg swelling
Symptom relief Not yet recruitingThis study tests whether a device that delivers sound waves (shock wave therapy) can help reduce leg swelling and improve quality of life in people with lower limb lymphedema. Thirty-six adults who are already using standard care will either get real or fake (sham) treatments twi…
Phase: NA • Sponsor: Gazi University • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
New device aims to ease leg swelling in lymphedema patients
Symptom relief Not yet recruitingThis study tests if a new dynamic compression device, used with compression stockings, works as well as current treatments for reducing leg swelling in people with lymphedema. About 98 adults with stage II or III lymphedema will use either the new device or standard wraps and pum…
Phase: NA • Sponsor: Jean-Paul Belgrado • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
Pre-transplant workout may shield heart in older leukemia patients
Symptom relief Not yet recruitingThis study tests a home-based exercise program called CAREFit-BMT for people with high-risk acute myeloid leukemia who are about to have a stem cell transplant. The program includes aerobic and strength training to improve heart function before the procedure. Researchers will enr…
Phase: NA • Sponsor: University of Washington • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
New shot for teen hay fever? early trial underway
Symptom relief Not yet recruitingThis phase 2 trial tests the safety of stapokibart injection in 15 teenagers aged 12-17 with seasonal allergic rhinitis (hay fever). Participants receive the drug alongside their usual allergy treatments. The study focuses on side effects and how the body processes the drug, not …
Phase: PHASE2 • Sponsor: Chengdu Kangnuoxing Biopharma,Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
New nasal spray aims to unblock stuffy noses fast
Symptom relief Not yet recruitingThis study looks at how well RHINOSEDAL works for people aged 8 and older with a stuffy nose caused by colds, allergies, or sinus issues. About 126 participants will use the treatment as prescribed and report their symptoms over 6 days. The goal is to see if it provides meaningfu…
Sponsor: Laboratoires Elerte • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
Lupus brain fog? a simple exercise program might help clear it
Symptom relief Not yet recruitingThis study looks at whether a 12-week aerobic exercise program can improve thinking skills and reduce disease activity in people with lupus. Researchers will test memory, attention, and walking ability before and after the program. The goal is to see if exercise can ease lupus-re…
Phase: NA • Sponsor: Istanbul Galata University • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New monthly shot could ease Sjögren's dry mouth
Symptom relief Not yet recruitingThis phase 3 study tests whether ianalumab, given as a monthly injection, can reduce dry mouth and other symptoms in people with Sjögren's disease who have a high symptom burden. About 570 adults will receive either the drug or a placebo for 52 weeks. The main goal is to see if t…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Could pressurized oxygen ease chronic fatigue? new trial aims to find out
Symptom relief Not yet recruitingThis study tests whether breathing pure oxygen in a pressurized chamber (hyperbaric oxygen therapy) can help people with mild to moderate chronic fatigue syndrome. 74 participants will receive either real treatment or a sham (placebo) for 60 sessions over 3 months. Researchers wi…
Phase: NA • Sponsor: Assaf-Harofeh Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New compression device could ease lymphedema swelling faster
Symptom relief Not yet recruitingThis study compares a new dynamic compression device to traditional bandages for reducing leg swelling in people with lymphedema. Over 5 days of intensive treatment, 110 participants will wear either the device or standard bandages. The goal is to see which method reduces excess …
Phase: NA • Sponsor: Jean-Paul Belgrado • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Iron pills may ease eczema in teens, new study hopes to prove
Symptom relief Not yet recruitingThis study tests whether adding oral iron supplements to standard eczema treatment can reduce skin symptoms and improve quality of life in adolescents aged 12 to 16 with mild to moderate atopic dermatitis. Researchers will also check if iron levels in the blood affect how well th…
Phase: NA • Sponsor: Cairo University • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Virtual park ride could boost rehab motivation for brain conditions
Symptom relief Not yet recruitingThis study tests whether using a virtual reality (VR) system during cycling exercise makes rehabilitation more motivating for adults with conditions like stroke, Parkinson's, multiple sclerosis, or frailty. About 70 participants will try cycling with and without VR over 4 weeks. …
Phase: NA • Sponsor: Marta Mondellini • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Tailored exercise may ease walking troubles for hispanics with MS
Symptom relief Not yet recruitingThis study tests a 16-week exercise program designed specifically for Hispanic people with multiple sclerosis who have walking problems. About 66 participants will either join the exercise group or a waitlist. The goal is to see if the program improves walking ability and quality…
Phase: NA • Sponsor: The University of Texas Health Science Center, Houston • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
Can an online program help young people with lupus and dermatomyositis feel less stressed?
Symptom relief Not yet recruitingThis study tests a new online program called TEAM-LEADS designed to help teens and young adults (ages 13-22) with lupus or dermatomyositis reduce stress and improve heart-healthy behaviors like diet, exercise, and sleep. The program is self-guided and completed online. The study …
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Could breathing different oxygen levels ease chronic fatigue?
Symptom relief Not yet recruitingThis study tests a treatment called Intermittent Hypoxia-Hyperoxia Treatment (IHHT) for people with ME/CFS or long COVID. The therapy uses a mask to deliver short cycles of low and high oxygen, aiming to improve energy and reduce inflammation. 104 patients will be randomly assign…
Phase: NA • Sponsor: University of Aarhus • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Could a wakefulness drug beat fatigue in IBD patients?
Symptom relief Not yet recruitingThis study tests whether modafinil, a drug used for sleep disorders, can reduce severe fatigue in adults with inactive inflammatory bowel disease (IBD). Sixty participants will take either modafinil or a placebo for 8 weeks, starting at 100 mg daily with possible dose increases. …
Phase: PHASE2, PHASE3 • Sponsor: Radboud University Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
New gel could soothe eczema symptoms in early trial
Symptom relief Not yet recruitingThis study tests a gel called VC005 on adults with mild to moderate atopic dermatitis (eczema). About 120 participants will use either the gel or a placebo to see if it safely reduces skin redness, itching, and rash. The goal is to ease symptoms, not cure the condition.
Phase: PHASE2 • Sponsor: Jiangsu vcare pharmaceutical technology co., LTD • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
New allergy spray trial aims to help teens breathe easier
Symptom relief Not yet recruitingThis study tests if Dymista nasal spray safely eases allergy symptoms like sneezing, stuffy nose, and itchy eyes in Chinese teenagers aged 12 to 17. About 100 participants will use the spray twice daily for two weeks. The goal is to see if symptoms improve, not to cure allergies.
Phase: PHASE4 • Sponsor: Viatris Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Essential oils tested as a natural remedy for MS bladder issues
Symptom relief Not yet recruitingThis study tests whether a daily topical blend of lavender and rosemary essential oils can reduce urinary urgency, frequency, and leakage in adults with multiple sclerosis. Sixty participants will use either the essential oil blend or a placebo oil for six weeks. Researchers will…
Phase: NA • Sponsor: University of Oran 1 • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Partial tonsil surgery may cut sick leave and opioid use
Symptom relief Not yet recruitingThis study compares two tonsil surgery methods in adults: full removal (extracapsular) and partial removal (intracapsular). The goal is to see if partial surgery allows a shorter sick leave and less need for opioid painkillers, while still being as effective at relieving tonsilli…
Phase: NA • Sponsor: Turku University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Could a magnetic headset boost brain power after injury or illness?
Symptom relief Not yet recruitingThis early study tests whether a low-level magnetic therapy device, used at home, is safe and practical for people with cognitive issues from brain injury, Long COVID, or Alzheimer's. About 30 adults will use the device regularly and complete computer-based thinking tests. The go…
Phase: NA • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
HIIT workouts may boost mobility and brain function in MS patients
Symptom relief Not yet recruitingThis study will test whether high-intensity interval training (HIIT) on a stationary bike can improve walking, balance, and thinking in people with multiple sclerosis (MS). Forty adults with mild to moderate MS will be randomly assigned to either HIIT or moderate-intensity contin…
Phase: NA • Sponsor: Hacettepe University • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
New HIV prevention drug faces drug interaction test
Knowledge-focused Not yet recruitingThis early-stage study looks at how a common tuberculosis drug, rifampin, affects levels of a new HIV prevention medicine called MK-8527. Fourteen adults with latent TB (no active symptoms) will take MK-8527 with and without rifampin. The goal is to see if the two drugs can be us…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Dutch hospital data reveals hidden patterns in IBD treatment
Knowledge-focused Not yet recruitingThis study looks at medical records from thousands of adults with Crohn's disease or ulcerative colitis treated in Dutch hospitals between 2018 and 2026. Researchers will analyze which treatments patients receive, how often they switch therapies, and how the disease affects other…
Sponsor: LOGEX • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Scientists launch deep dive into IBD to uncover hidden clues
Knowledge-focused Not yet recruitingThis study will follow 100 adults with Crohn's disease, ulcerative colitis, or other IBD, plus their healthy relatives, for up to 3 years. Researchers will collect blood, stool, tissue samples, and imaging to track how immune cells and genetics change over time. The goal is to fi…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Could you help scientists unlock genetic cancer secrets?
Knowledge-focused Not yet recruitingThis study screens up to 1,000 people with personal or family histories of certain cancers to see if they qualify for ongoing genetics research at the National Cancer Institute. Participants fill out a 15-20 minute online survey about their health and family history. No treatment…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Acupuncture points may signal hidden disease activity
Knowledge-focused Not yet recruitingThis study investigates whether acupuncture points become tender or more sensitive in people with inflammatory bowel disease (IBD), such as Crohn's disease or ulcerative colitis. Researchers will compare skin temperature, blood flow, and pain sensitivity at specific body points b…
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Dermatology study aims to cut unnecessary clinic visits with simple surveys
Knowledge-focused Not yet recruitingThis study tests whether letting patients report their symptoms online can help doctors schedule follow-up visits only when needed. About 250 adults with chronic skin conditions like eczema or psoriasis will either get standard fixed appointments or flexible scheduling based on m…
Phase: NA • Sponsor: National University Hospital, Singapore • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
New glucose monitor aims for pinpoint accuracy in diabetes care
Knowledge-focused Not yet recruitingThis pilot study tests a new continuous glucose monitor (CGM) called SAVA in 20 adults with Type 1 Diabetes. Participants wear three SAVA sensors and one standard sensor for 15 days to check how well the SAVA measures blood sugar compared to lab tests. The study also looks at com…
Phase: NA • Sponsor: SAVA Technologies Ltd. • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Could poor balance be the hidden link between MS fatigue and fear of falling?
Knowledge-focused Not yet recruitingThis study investigates whether balance problems explain why fatigue leads to a greater fear of falling in people with multiple sclerosis (MS). Researchers will assess fatigue, balance, and fear of falling in 40 adults with MS who can walk independently or with a device. The goal…
Sponsor: Uskudar University • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Hidden toll of myasthenia gravis: study probes sexual and bladder problems often overlooked
Knowledge-focused Not yet recruitingThis study investigates sexual and urinary problems in people with generalized myasthenia gravis, an autoimmune disease that causes muscle weakness. While visible symptoms like droopy eyelids are well-known, issues like sexual dysfunction and bladder problems are often ignored. R…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Could a simple blood test predict lupus in children with ITP?
Knowledge-focused Not yet recruitingThis study looks at children with immune thrombocytopenic purpura (ITP) who also have certain antibodies, as they are at higher risk of developing lupus. Researchers will analyze blood samples to track immune cell changes and markers that may signal the transition to lupus. The g…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
New study tracks hidden dangers of common leukemia drug
Knowledge-focused Not yet recruitingThis study will follow 200 children with acute lymphoblastic leukemia or lymphoma to learn more about the short- and long-term side effects of asparaginase drugs. Researchers will track how often serious toxicities occur during standard treatment and a newer therapy called SJALL2…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Genetic clue may unlock why lupus hits some people harder
Knowledge-focused Not yet recruitingThis study investigates whether a specific gene variation (ICOS) is linked to developing systemic lupus erythematosus (SLE) and how severe the disease becomes. Researchers will analyze blood samples from 30 people diagnosed with SLE to look for patterns in the ICOS gene. The goal…
Sponsor: South Valley University • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Will a new drug form work the same? study tests two versions of SKI-O-703
Knowledge-focused Not yet recruitingThis study tests whether two different capsule forms of the experimental drug SKI-O-703 are absorbed similarly in the body. About 48 healthy adults (Korean and Caucasian) will take a single dose of each form on separate days, with blood samples taken to compare drug levels. The r…
Phase: PHASE1 • Sponsor: Oscotec Inc. • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Will a sticky patch stay put? study tests future pump design on kids
Knowledge-focused Not yet recruitingThis study tests how well the adhesive parts of a future patch pump stick to the skin of children aged 7 to 17 who need insulin for diabetes. The device is a dummy—it has no electronics and just mimics the shape and weight of a real pump. Researchers will see if the patch stays a…
Sponsor: Medtronic MiniMed, Inc. • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Home devices may spot lung flare-ups before they become emergencies
Knowledge-focused Not yet recruitingThis study tests whether people with fibrotic interstitial lung disease can use home monitoring devices—like a spirometer, pulse oximeter, and scale—to help detect serious lung events such as flare-ups or hospitalizations. About 200 participants will use these devices connected t…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Could HIV treatment choice affect sleep? new study investigates
Knowledge-focused Not yet recruitingThis study looks at sleep health in people with HIV who are on different antiretroviral therapies. Some participants switch from a dolutegravir-based regimen to a doravirine-based one, while others stay on dolutegravir. Sleep is measured using questionnaires, wrist-worn activity …
Phase: PHASE4 • Sponsor: University of Witwatersrand, South Africa • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Smartwatches may spot IBD flares before symptoms start
Knowledge-focused Not yet recruitingThis study explores whether changes in heart rate, sleep, and activity measured by a person's own smartwatch can predict flare-ups in inflammatory bowel disease (IBD). Six hundred adults with Crohn's disease or ulcerative colitis who already own a compatible device will participa…
Sponsor: Maastricht University Medical Center • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Radioactive tracer reveals how potential Crohn's drug moves through the body
Knowledge-focused Not yet recruitingThis trial in 8 healthy men aged 30–65 examines how the body absorbs, breaks down, and eliminates ontunisertib, an experimental oral drug for fibrostenotic Crohn's disease. Participants receive a single dose of the drug with a radioactive label, allowing researchers to track its …
Phase: PHASE1 • Sponsor: Agomab Spain S.L.U. • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Can a simple social check improve leukemia care?
Knowledge-focused Not yet recruitingThis study looks at whether screening adults with leukemia for social needs (like housing or food) and offering early social work help is practical and helpful. About 80 newly diagnosed patients will either get the screening and consultation or usual care. The goal is to see if t…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Baby blood test could predict type 1 diabetes risk
Knowledge-focused Not yet recruitingThis study aims to identify newborns with a high genetic risk of developing type 1 diabetes. Researchers will screen 50,000 infants using a simple genetic test to find those with a greater than 10% risk. The goal is not to treat diabetes, but to find eligible babies for future pr…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New study examines belantamab combos for myeloma relapse
Knowledge-focused Not yet recruitingThis observational study will review medical records of about 100 adults with multiple myeloma that has returned after initial treatment. Researchers want to see how well belantamab mafodotin given with other drugs (bortezomib and dexamethasone, or pomalidomide and dexamethasone)…
Sponsor: PETHEMA Foundation • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
New foot scanner aims to help diabetics spot problems early
Knowledge-focused Not yet recruitingThis pilot study will test how easy it is for 20 adults with diabetes to set up and use the Feetsee foot monitoring device at home over 8 weeks. Participants will use the device and app on their own, following the instructions provided. The goal is to see if people can use it cor…
Sponsor: Diabetis JSC • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
New ultrasound aims to spot twin pregnancy complications before they start
Knowledge-focused Not yet recruitingThis study will test a new, high-speed ultrasound device on 10 healthy women pregnant with identical twins who share a placenta. The goal is to see if the device can take detailed pictures of the tiny blood vessels in the placenta. This information could help doctors better under…
Phase: NA • Sponsor: Carilion Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
800-Patient study aims to unlock secrets of autoimmune liver disease
Knowledge-focused Not yet recruitingThis French study will collect medical data and biological samples from 800 people with autoimmune liver diseases. Researchers hope to identify new markers that explain why some patients respond well to treatment while others do not. The goal is to better understand the immune me…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Can AI predict heart trouble in IBD patients?
Knowledge-focused Not yet recruitingThis study looks at people with inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, to better understand their risk of serious heart problems like stroke and heart attack. Researchers will collect information on therapy, disease activity, lifestyle…
Sponsor: IRCCS Policlinico S. Donato • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Phone vs. mail: which gets more people to screen for type 1 diabetes?
Knowledge-focused Not yet recruitingThis study compares two ways of inviting people to screen for type 1 diabetes at home: a simple email or letter versus a personal phone call. Researchers want to see which method leads more people to complete and return a home screening kit. Participants are adults and children a…
Phase: NA • Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Study examines which IBD drugs are safer for seniors
Knowledge-focused Not yet recruitingThis study looked at nearly 24,000 older adults (65+) with ulcerative colitis or Crohn's disease to see if certain advanced treatments lead to more infections. Researchers compared patients taking ENTYVIO, TNF-alpha inhibitors, or ustekinumab using Medicare claims data from 2016 …
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Scientists hunt for clues to rare CAR-T side effects in myeloma
Knowledge-focused Not yet recruitingThis observational study will follow 30 multiple myeloma patients receiving a standard CAR-T therapy called cilta-cel. Researchers will collect blood, bone marrow, and other samples to find biomarkers linked to rare toxicities like nerve damage, blood issues, and gut problems. Th…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Blood test may reveal if allergy treatment is effective
Knowledge-focused Not yet recruitingThis study aims to develop a blood test that measures B regulatory cells, which may indicate whether allergen immunotherapy (allergy shots) is successfully reducing allergic reactions. Researchers will study 80 adults with pollen or venom allergies who are starting routine allerg…
Sponsor: Hull University Teaching Hospitals NHS Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Scientists investigate how immune cells fight leukemia
Knowledge-focused Not yet recruitingThis study will collect blood and bone marrow samples from 55 adults with acute leukemia or myelodysplastic syndrome. Researchers want to understand how natural killer (NK) cells interact with cancer cells over time. The goal is to identify genetic markers and immune patterns tha…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Simple CT scan could reveal hidden heart risks in HIV patients
Knowledge-focused Not yet recruitingThis study investigates whether a simple coronary CT scan can detect early signs of heart disease in people with HIV. Researchers will measure calcium buildup in the heart arteries of 384 Mexican adults with HIV who have undetectable viral loads. The goal is to better understand …
Sponsor: Instituto Mexicano del Seguro Social • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Water pH may impact colonoscopy cleanliness in First-of-Its-Kind study
Knowledge-focused Not yet recruitingThis study will look at 1,200 people getting a colonoscopy to see if the pH of the water they drink during bowel preparation affects how clean their colon is. Researchers will note the pH of each person's drinking water and rate bowel cleanliness using a standard scale. This is t…
Sponsor: Sinan Ömeroğlu, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Could cousins be as good as siblings for stem cell donation?
Knowledge-focused Not yet recruitingThis study looks at whether using a cousin as a stem cell donor works as well as using a sibling for people with blood cancers. Researchers will compare survival, relapse, and side effects like graft-versus-host disease in patients who received a transplant from either a cousin o…
Sponsor: The First Affiliated Hospital of Soochow University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Brain fog after lymphoma: study probes lasting cognitive effects of chemotherapy
Knowledge-focused Not yet recruitingThis study looks at thinking skills, memory, and quality of life in people who are 3 to 5 years past successful treatment for Hodgkin lymphoma or certain types of B-cell lymphoma. Participants take a series of tests and questionnaires once during a regular follow-up visit. The go…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Scientists create atlas of rare lymphoma to unlock new treatment clues
Knowledge-focused Not yet recruitingThis observational study will analyze tissue samples from 400 people with MALT lymphoma, a slow-growing cancer. Researchers aim to build a comprehensive molecular and cellular map of the disease across different body sites. The goal is to identify tumor subtypes and biomarkers th…
Sponsor: International Extranodal Lymphoma Study Group (IELSG) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Could skipping bowel prep before colon surgery be just as safe?
Knowledge-focused Not yet recruitingThis study looks at whether it's safe to skip mechanical bowel preparation (the drink that cleans out your colon) before colon surgery. Currently, the best practice combines that drink with antibiotics to prevent infections. The trial will compare two groups: one getting the drin…
Phase: NA • Sponsor: Mount Sinai Hospital, Canada • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Long-Term study aims to unlock mystery of joint hypermobility and chronic illness
Knowledge-focused Not yet recruitingThis study will follow 100 health science students for at least 10 years to understand why some people with very flexible joints (hypermobility) develop chronic pain, fatigue, and other health issues while others do not. Researchers will measure balance, heart rate, and quality o…
Sponsor: Clarkson University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New study to reveal hidden immune effects of common leukemia drug
Knowledge-focused Not yet recruitingThis study will observe 10 adults with acute myeloid leukemia who are receiving the drug gilteritinib after a stem cell transplant. Researchers want to understand how gilteritinib affects the behavior, metabolism, and function of immune cells like T-cells and monocytes. The goal …
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Scientists map the genetic secrets of a rare brain cancer to pave the way for smarter treatments
Knowledge-focused Not yet recruitingThis study examines tumor samples from 100 people diagnosed with primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL), a rare cancer that starts in the brain or spine. Researchers will use advanced genetic and molecular techniques to identify patterns in the …
Sponsor: International Extranodal Lymphoma Study Group (IELSG) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New study aims to understand physical challenges in kids with nerve diseases
Knowledge-focused Not yet recruitingThis study will look at balance, core strength, leg strength, walking ability, and fatigue in 32 children aged 6-18 with demyelinating diseases (conditions affecting the protective coating of nerves). Each child will undergo a single session of non-invasive tests like balance exe…
Sponsor: Istanbul University - Cerrahpasa • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Hemp seed allergy risk under the microscope: new study launches
Knowledge-focused Not yet recruitingThis study will test 35 people with known or suspected allergies to cannabis, tree nuts, or seeds to see if they are also allergic to hemp seeds. Participants will receive skin prick tests and blood tests to measure allergic reactions. The goal is to understand the potential alle…
Phase: NA • Sponsor: University Hospital, Angers • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Blood test could predict bleeding risk in cancer patients
Knowledge-focused Not yet recruitingThis study aims to create a score that uses a special blood test to predict bleeding risk in people with blood cancers and very low platelet counts. Researchers will take an extra blood sample from 410 participants and analyze it with viscoelastometric tests. The goal is to ident…
Sponsor: Centre Hospitalier Annecy Genevois • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study to measure drug levels in breast milk of moms on TREMFYA
Knowledge-focused Not yet recruitingThis study will measure how much of the drug TREMFYA (guselkumab) passes into breast milk of 10 nursing women who are already taking it for conditions like psoriasis, psoriatic arthritis, ulcerative colitis, or Crohn's disease. Researchers will collect milk samples to estimate th…
Phase: PHASE4 • Sponsor: Janssen Research & Development, LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Stomach cancer study may spare some patients unnecessary surgery
Knowledge-focused Not yet recruitingThis study looks at whether a tumor's DNA repair status (MMR) changes how well the presence of cancer cells in lymph vessels predicts spread to lymph nodes in stomach cancer. Researchers will review medical records of 3,000 patients who had surgery. The goal is to improve risk as…
Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Personalized videos may make colonoscopy prep easier for IBD patients
Knowledge-focused Not yet recruitingThis study tests whether watching a short video tailored to their specific type of inflammatory bowel disease (IBD) helps patients better prepare their bowel for a colonoscopy. About 600 adults with ulcerative colitis or Crohn's disease will be randomly assigned to receive either…
Phase: NA • Sponsor: Jie Liang • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Blood fats and nanoparticles may reveal hidden clues in autoimmune liver disease
Knowledge-focused Not yet recruitingThis study looks at two types of liver disease — autoimmune hepatitis and non-alcoholic fatty liver disease — to see if fats in blood cells and tiny particles called extracellular vesicles differ between them. Researchers will collect blood samples from 24 adults and analyze thes…
Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists build lab models of scleroderma from Patients' blood cells
Knowledge-focused Not yet recruitingThis study aims to create stem cell lines from blood samples of 16 people: 4 with severe scleroderma, 4 with mild scleroderma, and 8 of their healthy relatives. These stem cells will be turned into various tissue types (like heart, skin, and immune cells) in the lab to study how …
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Real-World study to track Eltrombopag's effectiveness in ITP patients
Knowledge-focused Not yet recruitingThis study looks at how eltrombopag is actually used and how well it works in patients with immune thrombocytopenia (ITP) who have already tried steroids. Researchers will collect data from healthcare providers in the US, UK, and Germany, focusing on platelet count improvements w…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Breastfeeding moms needed for drug safety study
Knowledge-focused Not yet recruitingThis study will measure how much of the drug mirikizumab passes into breast milk in 14 breastfeeding women who take it for inflammatory bowel disease. Participants will provide milk samples over several weeks. The goal is to understand potential exposure to nursing infants, helpi…
Phase: PHASE4 • Sponsor: Eli Lilly and Company • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Blood marker may reveal hidden inflammation in arthritis patients
Knowledge-focused Not yet recruitingThis study will measure a protein called IL-41 in the blood of 90 people with ankylosing spondylitis or psoriatic arthritis, plus healthy volunteers. Researchers want to see if higher levels of this protein are linked to more active disease. The goal is to find a simple blood tes…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New scan technique could sharpen cancer imaging
Knowledge-focused Not yet recruitingThis pilot study tests a new imaging method called PET-enabled dual-energy CT to measure bone and soft tissue in the bone marrow. It will include 45 adults: some with multiple myeloma scheduled for CAR T-cell therapy and some healthy volunteers. The goal is to see if this new met…
Phase: NA • Sponsor: University of California, Davis • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
HIV study aims to uncover hidden health risks in aging patients
Knowledge-focused Not yet recruitingThis study will look at over 12,000 adults in the Basque Country to compare how common multiple health conditions, taking many medications, and getting risky prescriptions are among people with HIV versus the general population. Researchers will use electronic health records to g…
Sponsor: Biogipuzkoa Health Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Can blood tests and scans track lymphoma in real time? new study aims to find out.
Knowledge-focused Not yet recruitingThis study will test whether doctors can quickly and accurately monitor minimal residual disease (tiny amounts of cancer left after treatment) in people with aggressive B-cell lymphoma. Researchers will use blood tests to look for tumor DNA and PET scans to see if results can be …
Sponsor: The Lymphoma Academic Research Organisation • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Could blocking TL1A stop skin scarring in scleroderma? early lab study hints at possibility
Knowledge-focused Not yet recruitingThis study will test if blocking a protein called TL1A can reverse skin scarring in systemic sclerosis, a rare autoimmune disease. Researchers will take blood and skin samples from 10 patients with early diffuse scleroderma and 10 healthy people. They will treat the samples in th…
Sponsor: Fondazione Policlinico Universitario Campus Bio-Medico • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Can exercise tame the immune system in MS? new study investigates
Knowledge-focused Not yet recruitingThis study looks at how different types of exercise—aerobic and resistance training—affect the immune system and physical abilities in people with relapsing-remitting multiple sclerosis (MS). Researchers will measure changes in blood markers of inflammation and functional tests l…
Phase: NA • Sponsor: Seda Saka • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
New study tests if SPECT imaging can forecast prostate cancer treatment success
Knowledge-focused Not yet recruitingThis study will look at whether SPECT scans taken after Lu-PSMA therapy can help predict how well patients with metastatic castration-resistant prostate cancer (mCRPC) are doing. Researchers will measure tumor activity and volume on the scans and compare them to standard PET-base…
Sponsor: Central Hospital, Nancy, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Can when you eat protect your brain from MS?
Knowledge-focused Not yet recruitingThis study looks at whether the time of day you eat can affect brain health in people with multiple sclerosis. Twenty-two adults with MS will follow a daily eating schedule for a set period. Researchers will measure markers of nerve health and inflammation in the blood. A small g…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Hidden nerve damage may worsen life for ankylosing spondylitis patients
Knowledge-focused Not yet recruitingThis study will check 45 adults with ankylosing spondylitis for peripheral neuropathy (nerve damage in the arms and legs) using nerve conduction tests. Researchers want to see if nerve problems are linked to higher disease activity, increased pain sensitivity, and worse quality o…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
HIV and fatty liver: scientists hunt for hidden clues in the blood
Knowledge-focused Not yet recruitingThis study looks at how HIV might change the way the body handles fats in the liver, leading to fatty liver disease. Researchers will collect one blood sample from 120 adults: people with HIV and fatty liver, people without HIV but with fatty liver, and healthy controls. By analy…
Sponsor: Yinzhong Shen • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Scientists hunt for clues to chemo resistance in blood cancer
Knowledge-focused Not yet recruitingThis study collects blood and bone marrow samples from 80 people with B-cell non-Hodgkin lymphoma to explore why some cancers resist chemotherapy. Researchers will analyze the tumor and its environment, and develop lab models to test new treatments. The goal is to uncover resista…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Massive MS study aims to unlock secrets of disability progression
Knowledge-focused Not yet recruitingThis study will follow 2,000 people with multiple sclerosis (MS) for five years to understand why some get worse faster than others. Researchers will use brain scans, eye exams, blood tests, and activity monitors to track changes. The goal is to find factors—like inflammation, bl…
Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
New study to see how well two glucose monitors track blood sugar
Knowledge-focused Not yet recruitingThis study will test how accurate and safe two continuous glucose monitoring (CGM) systems, the Anytime 5Pro and Anytime 4Pro, are in adults with type 1 or type 2 diabetes. About 70 participants will wear both devices at the same time and have their blood sugar measured during cl…
Phase: NA • Sponsor: Yuwell Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Blood test could predict vasculitis relapse, study hopes
Knowledge-focused Not yet recruitingThis study follows 120 adults with ANCA-associated vasculitis, an autoimmune disease, who are receiving rituximab therapy. Researchers will collect blood samples over time to look for immune cell changes that signal a coming relapse. The goal is to find biomarkers that help docto…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Why do blood cancer patients skip home care? new study aims to find out.
Knowledge-focused Not yet recruitingThis study looks at why some people with blood cancers like multiple myeloma or lymphoma choose not to receive treatment at home, or are not eligible for it. Researchers will interview patients, their caregivers, and healthcare staff, and review medical records and questionnaires…
Sponsor: Odense University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
New study aims to unravel mysteries of common inflammatory condition in older adults
Knowledge-focused Not yet recruitingThis study will follow 400 people recently diagnosed with polymyalgia rheumatica, a condition causing shoulder and hip pain. Researchers will track symptoms, treatments, and outcomes over 5 years to better understand the disease and improve diagnosis. Participants will provide bl…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Could cutting salt soothe your skin? new study investigates
Knowledge-focused Not yet recruitingThis study looks at whether changing how much salt you eat can affect skin sodium levels and the severity of eczema or psoriasis. Fifty adults will follow a low-salt diet and take either sodium tablets or a placebo for several weeks. The goal is to see if this approach is practic…
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Tiny plastics in our food may fuel Crohn's inflammation, scientists investigate
Knowledge-focused Not yet recruitingThis study will look at whether tiny plastic particles found in food and water are linked to Crohn's disease. Researchers will compare 90 people—some with Crohn's and some without—to see if those with Crohn's have more plastic particles in their blood and gut, and how that affect…
Sponsor: Mak Wing Yan • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
New study aims to boost cervical cancer screening for women with HIV
Knowledge-focused Not yet recruitingThis study looks at how to make cervical cancer screening easier for women with HIV, who are at higher risk for this cancer. Researchers will talk to patients and doctors to find out what gets in the way of screening and follow-up care. They will also explore using HPV self-testi…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Heart scarring in HIV: researchers probe substance use link
Knowledge-focused Not yet recruitingThis observational study will use cardiac MRI to examine how stimulant and polysubstance use affects heart scarring and inflammation in 400 people with and without HIV. Participants will have one study visit for a detailed heart scan. The goal is to better understand the combined…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Grain-of-Rice device could end guesswork in skin treatment
Knowledge-focused Not yet recruitingThis study tests a tiny microdevice, about the size of a grain of rice, that holds up to 20 different FDA-approved skin medications. Placed directly on the skin, it releases very small amounts of each drug to see how the skin reacts. The goal is to find out if this device can saf…
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Can a quick quiz replace gym tests for kids with chronic illness?
Knowledge-focused Not yet recruitingThis study checks whether two short questionnaires can accurately measure physical fitness in children aged 10–18 with juvenile idiopathic arthritis or familial Mediterranean fever. Researchers will compare the questionnaire results with standard fitness tests. If the questionnai…
Sponsor: Istanbul University - Cerrahpasa • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Blood test may spare thousands from unnecessary colon surgery
Knowledge-focused Not yet recruitingThis study will collect blood samples from 1,000 people with small colon growths to see if a liquid biopsy can accurately tell benign from malignant lesions and predict cancer spread to lymph nodes. Current methods often lead to unnecessary surgery. The goal is to create a bioban…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Italian study to track CAR-T success in leukemia patients
Knowledge-focused Not yet recruitingThis observational study will follow 107 children and adults with B-cell acute lymphoblastic leukemia who are treated with approved CAR-T cell therapies in Italy. Researchers will collect data from medical records to see how many patients achieve a response. The goal is to unders…
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New hope for rare blood disorder: study reviews real-world use of enzyme therapy
Knowledge-focused Not yet recruitingThis study looks back at medical records of people with congenital thrombotic thrombocytopenic purpura (cTTP), a rare inherited blood disorder that causes dangerous blood clots. Participants received a manufactured version of the missing ADAMTS13 enzyme through an early access pr…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New study aims to crack the code of treatment resistance in lymphoma
Knowledge-focused Not yet recruitingThis study will follow 70 adults with relapsed or refractory B-cell non-Hodgkin lymphoma who are receiving bispecific antibody therapy. Researchers want to understand why some patients don't respond or develop serious side effects. They will look at tumor samples, gut bacteria, a…
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New study aims to predict which lymphedema patients benefit from surgery
Knowledge-focused Not yet recruitingThis study will test whether special imaging scans (ICG lymphography and high-frequency ultrasound) can predict how well a surgery called lymphaticovenous anastomosis works for arm swelling after breast cancer treatment. Thirty women with mild to moderate lymphedema will be scann…
Phase: NA • Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Why do insulin shots leave marks? new study investigates skin complications in kids with diabetes
Knowledge-focused Not yet recruitingThis study looks at 199 children with type 1 diabetes who have been using insulin for at least 6 months. Researchers will check for skin problems like lumps under the skin (lipohypertrophy) caused by injections. They will also measure fat thickness with ultrasound and ask caregiv…
Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Simple skin test may prevent chemotherapy allergies
Knowledge-focused Not yet recruitingThis study tests whether a skin test can predict allergic reactions to the chemotherapy drug oxaliplatin. About 380 cancer patients will receive a tiny amount of oxaliplatin under the skin before their regular treatment. Researchers will check if the skin test results match who a…
Phase: NA • Sponsor: Fujian Cancer Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Can a smarter sleeve beat lymphedema?
Knowledge-focused Not yet recruitingThis pilot study tests whether a new compression pattern in a leg sleeve device (Flexitouch Plus) moves lymph fluid better than the current version. Five adults with leg lymphedema will receive both treatments in separate visits, and doctors will measure how far and how often lym…
Phase: EARLY_PHASE1 • Sponsor: Tactile Medical • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Can a simple supplement protect transplant patients? healthy volunteers pave the way
Knowledge-focused Not yet recruitingThis early-stage study tests whether healthy volunteers can regularly take two natural gut supplements, propionate and butyrate, which are normally made by the body. The goal is to see if this approach is safe and practical before trying it in patients receiving donor stem cell t…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
Routine checkups could catch type 1 diabetes early
Knowledge-focused Not yet recruitingThis study looks at whether it's possible to screen children for type 1 diabetes during their regular well-child visits. Researchers will ask parents and doctors about their experience with the screening and track how many families complete the test. The goal is to find the best …
Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
Stomach acid pill may change how new myelofibrosis drug works
Knowledge-focused Not yet recruitingThis early-stage study in 16 healthy adults checks if taking a common stomach acid drug (rabeprazole) changes how the body absorbs a new experimental drug (TQ05105) being developed for myelofibrosis. Participants take TQ05105 alone and later with rabeprazole to compare drug level…
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
New blood test may predict cancer relapse after transplant
Knowledge-focused Not yet recruitingThis study is testing a new blood test called AlloHeme that looks for tiny traces of a patient's own cells after a stem cell transplant. The goal is to see if the test can predict whether leukemia or MDS will come back before it happens. About 400 adults who have had or will have…
Sponsor: CareDx • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
New study checks liver impact on myeloma drug combo
Knowledge-focused Not yet recruitingThis early-phase study looks at how the drug combination BVd (belantamab mafodotin, bortezomib, and dexamethasone) is processed by the body in people with multiple myeloma who also have moderate liver problems. About 20 participants will be enrolled to compare drug levels and saf…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
New study asks: is this glucose monitor a Game-Changer for diabetes?
Knowledge-focused Not yet recruitingThis study will ask 75 people with diabetes and their healthcare providers about their experience using the Instara-1 continuous glucose monitor. Participants will wear the device and answer questionnaires about comfort, ease of use, and how it helps manage their diabetes. The go…
Sponsor: Getz Pharma • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
New study tracks how a Gut-Joint drug works in real time
Knowledge-focused Not yet recruitingThis study follows 75 adults with Crohn's disease or ulcerative colitis who are starting guselkumab, a drug used for inflammatory bowel disease. Researchers want to see if the drug also helps with joint pain and stiffness linked to spondyloarthritis. Participants will report symp…
Sponsor: NYU Langone Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Your phone could predict arthritis before it strikes
Knowledge-focused Not yet recruitingThis study tests whether smartphone data and optional smartwatches can detect early signs of psoriatic arthritis in people with psoriasis. About 3,458 adults with psoriasis but no arthritis will use an app that passively collects phone data. The goal is to develop algorithms that…
Sponsor: University of Oxford • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Stem cell harvest trial aims to unlock gene therapy for rare blood disorders
Knowledge-focused Not yet recruitingThis early-phase study at St. Jude Children's Research Hospital will test whether it is safe and possible to collect blood stem cells from 12 young adults with inherited bone marrow failure syndromes. Participants will receive two drugs (filgrastim and plerixafor) to move stem ce…
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Crohn's Patients' voices heard in new symptom study
Knowledge-focused Not yet recruitingThis study will interview 15 adults with stricturing Crohn's disease to learn which symptoms matter most to them and what early warning signs they notice. Researchers hope to use this information to create a better clinical assessment score. Participants will have a one-hour inte…
Sponsor: University Hospital, Grenoble • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Oxygen bubbles could tame IBD flares without drugs
Knowledge-focused Not yet recruitingThis study looks at a new way to control inflammation during flare-ups of Crohn's disease and ulcerative colitis. Researchers will take blood samples from 30 adults with severe IBD and test whether oxygen microbubbles can reprogram immune cells (monocytes) to produce fewer inflam…
Sponsor: University Hospital, Grenoble • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC